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 VEGF treatment during status epilepticus alters long-term hippocampal astrocyte morphology: 
A detailed description of astrocyte morphology and glutamate transporter patterns with and 
without administration of VEGF and seizure induction  
 
by 
Janice Rene Lenzer 
Advisor: Susan D. Croll 
VEGF treatment during pilocarpine-induced status epilepticus (SE) causes enduring preservation 
of behavioral function in rats in the absence of enduring neuroprotection (Nicoletti et al., 2010). 
In addition, VEGF treatment reduces hyperexcitability in hippocampal slices without altering 
neuronal membrane properties (McCloskey et al, 2005). Combined, these data suggest the 
possibility that other cells or mechanisms could be involved in the beneficial effects of VEGF 
during SE. Our laboratory is interested in the potential contribution of astrocytes to these effects. 
Astrocytes are not only reported to contribute to epileptiform discharges in the hippocampus 
(Tian et al., 2005; Kang et al., 2005) but also to express VEGF receptors (Krum & Rosenstein, 
2002). We previously reported that VEGF treatment significantly alters multiple astrocyte 
parameters such as cell soma size, branching complexity, branch volume, number of dendrites, 
nodes counts and highest order branching after SE. The current study investigated both astrocyte 
morphology and glutamate transporter expression one month after SE in animals treated with 
VEGF or inactivated VEGF during SE. Individual GFAP-immunostained astrocytes from both 
CA1 and the dentate gyrus hilus were traced using Neurolucida software (Microbrightfield Inc.), 
allowing morphological parameters to be analyzed via Branched Structure and Sholl analyses. In 
iv 
 
addition, Image J software was used to measure optical density in GLT1 (glial glutamate 
transporter 1)-immunostained sections. VEGF treatment during SE significantly prevented post-
SE increases in number of branch intersections, process length, and node count. Furthermore, an 
analysis of the distance to the nearest neighboring astrocyte revealed that VEGF treatment 
significantly increased inter-astrocyte distance. GLT1 immunoreactivity in VEGF treated 
animals was decreased compared to seized controls. VEGF treatment did not significantly alter 
the shape of the astrocytes but rather the branching complexity and size. Because cell 
morphology impacts cell physiology, it is possible that VEGF’s enduring effects on post-SE 
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Chapter 1: Introduction 
Epilepsy 
Epilepsy affects millions of people in the United States and around the world. It is comprised of 
a group of disorders, known as the “epilepsies”, and is characterized by periodic, recurrent 
spontaneous seizures. The epilepsies are among the most common neurological disorders for 
which there is no known cure, and they can lead to multiple debilitating impairments.  
The many types of seizures can be broadly categorized as generalized or partial seizures, 
with this classification determined by the origin of electrical signaling. Generalized seizures 
result from electrical activity of the entire brain, and are usually associated with a loss of 
consciousness.  Partial seizures are characterized by smaller initial foci and less common 
impairment in consciousness. Where the seizure begins or originates can be of great importance 
when considering treatments for individuals with epilepsy.  
Partial and generalized seizures can also be classified as idiopathic, symptomatic or 
cryptogenic based on etiology. Idiopathic seizures typically have either a genetic cause or are 
spontaneous with no identified cause, such as chemical imbalances, and result from abnormal 
neurotransmission. Typically there are no structural or functional abnormalities associated with 
idiopathic epilepsy. A few examples of idiopathic seizures are Juvenile Myoclonic Epilepsy and 
Childhood Absence Epilepsy under the classification of generalized seizures and Benign Focal 
Childhood Epilepsy under the classification of partial seizures. In symptomatic epilepsy, on the 
other hand, the cause has been identified; or if the cause is unknown but believed to be likely, the 
epilepsy is referred to as Cryptogenic.  A few examples of symptomatic epilepsy are West 
Syndrome and Lennox-Gastaut Syndrome under the classification of generalized seizures and 
Temporal Lobe Epilepsy or Frontal Lobe Epilepsy under the classification of partial seizures. 
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Symptomatic epilepsy is associated with structural and functional abnormalities that in some 
cases stem from a known cause such as traumatic brain injury (TBI) or are believed to result 
from another problem such as Cerebral Palsy or Rett’s Syndrome. 
One type of partial seizure, and the most common form of partial epilepsy is temporal 
lobe epilepsy (TLE). TLE patients are also the most likely to be eligible for surgical resectioning. 
However, this surgery is not successful for many who undergo the procedure. Despite the 
common feature of seizures originating in the temporal lobe, particularly the hippocampus and 
other limbic structures, the underlying mechanisms of pathology are varied and include, but are 
not limited to, trauma, tumors, vascular malformations and hippocampal sclerosis. There is high 
variability among the epilepsies from individual to individual and one advantage of TLE is that 
there appears to be similar patterns or trends that are observed across individuals. This 
characteristic makes TLE a prime candidate for investigation and for the development of animal 
models to address epilepsy treatment (Edward Bertram, 2009). TLE is associated with both 
simple and complex partial seizures and is likely to be the most common form of epilepsy 
because the temporal lobes appear to be the most epileptogenic region of the brain. In human 
patients, 90% of those with temporal epileptiform abnormalities have a history of seizures 
(David Ko, 2012 Medscape).  
Individuals diagnosed with epilepsy, especially TLE, typically experience 
neuroanatomical and neurophysiological changes at both the cellular and molecular level. 
Additionally, those with chronic seizures experience cognitive, emotional and social impairments 
(Briellmann et al., 2002; Ozkara et al., 2004; Thompson & Duncan, 2005; Locke et al., 2010).  
Animals (Mortazavi et al., 2005; Gröticke et al., 2007) with chronic epilepsy also exhibit 
behaviors associated with anxiety and depression, deficits in learning and memory, and motor 
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impairments.  These functional impairments are hypothesized to be due to neuronal damage, 
circuit imbalance, hypoxic conditions and altered metabolism. Anatomical and physiological 
abnormalities have been reported in the hippocampus after severe seizures such as status 
epilepticus in animal models (Borges et al, 2003), and morphological changes have also been 
reported in cortical astrocytes (Ding et al, 2007). 
Status Epilepticus 
Regardless of the specific classification or etiology, episodes of status epilepticus can 
occur. Status Epilepticus (SE) is defined as a continuous seizure lasting more than 30 minutes or 
two or more seizures without full recovery of consciousness between them (Cherian & Thomas, 
2009). However, the defined time frame is dependent upon the method of investigation or the 
treatment type and ranges from 5 minutes to 90 minutes. In humans, it has been found that if SE 
lasts for five minutes, it will likely continue for at least twenty minutes but may spontaneously 
remit (Bassin et al., 2002). It is important to note that permanent neurological damage or 
pathophysiology can result from prolonged SE (Cherian & Thomas, 2009). Therefore it is 
important that treatment stop the seizure.  Some evidence also suggests that seizures may 
become refractory and difficult to control if treatment is delayed.  Animal models of epilepsy 
have reported significant structural brain damage after 30 minutes of SE (Scott et al., 1998). 
Results found in animal models don't always translate to humans and prove to be more difficult 
to explain or demonstrate in patients (Duncan, 2006). Thus, the extent of neuronal injury in 
humans due to seizure activity is currently unclear.  
Common causes of SE include, but are not limited to, brain injury, cerebrovascular 
disease, hypoxia/anoxia, tumor, infectious disease, drug and alcohol withdrawal, systemic and 
metabolic illnesses, and noncompliance with antiepileptic drugs in patients with epilepsy (Bassin 
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et al., 2002).  Based on a prospective population-based study conducted at the Medical College 
of Virginia, it is estimated that 100,000 cases of SE occur in the United States per year 
(DeLorenzo et al., 1996).  Recent reports of incidence approximate 50,000-150,000 cases present 
with mortality rates estimated from 10-40% (Coeytauz et al., 2000; DeLorenzo et al., 1996). The 
prevalence of epilepsy is high globally and incidence rates are growing due to the development 
of epilepsy following head trauma and co-morbid diseases. Once an individual is recognized as 
having seizure activity, the first line of treatment to prevent future seizures is anti-epileptic drug 
(AED) treatment. 
Epilepsy Treatments 
Current treatment options are dominated by AEDs such as Valproate, Tegretol, and 
Gabapentin. Although these drugs assist in reducing the seizures for most patients, about 30-40% 
of patients are either unresponsive or poorly responsive to AED therapy. Additionally, these 
pharmacological treatments do not usually address the origin or etiological mechanism of the 
seizures. However, they may reveal important information regarding the regions, channels, and 
cellular connections that contribute to seizure generation and activity. The pathways these drugs 
utilize in the system are a good place to begin animal model investigations and are used in 
experimental designs to examine questions regarding the changes that occur in chronic epilepsy 
patients. 
Many current pharmacological treatments for epilepsy act on widely expressed ion 
channels that directly control neuron excitability (Rogawski & Loscher, 2004). For instance 
Phenytoin, a drug that blocks certain sodium channels, reduces the rate of action potentials and 
therefore inhibits high-frequency firing of neurons. Another pharmacological option is 
phenobarbital, a GABA receptor agonist, which increases the efficacy at inhibitory synapses and 
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therefore attenuates excitability.  
There are non-pharmacological options for intractable epileptics that include surgical 
resectioning or electrical stimulation devices such as Vagus Nerve Stimulators as well as non-
invasive interventions such as the ketogenic diet and meditation. Only a small proportion of 
epilepsy patients are eligible for the invasive treatment options such as surgery; whereas the less 
invasive alternative methods are considered to be mostly complementary to the AED’s available 
and are used less often as monotherapy for those with chronic seizures.   
Because current treatment options for epilepsy do not offer successful control of seizures 
for a large portion of epilepsy patients, new treatment options are needed.  Experimental models 
of epilepsy have been used in the search for novel therapeutic targets. Current AEDs and other 
treatments are still focused on the immediate needs of the epileptic population and do not treat 
the etiological source of the problem, nor do they address preventive measures to avoid 
epileptogenesis or to protect against damage to brain structures in chronic epilepsy.  
Experimental Models of Epilepsy 
The use of animal models to further understand the changes in brain physiology and 
circuitry that occur during seizures has provided a great deal of information that could not be 
experimentally investigated using human subjects. Animal models have allowed researchers to 
examine similarities in the patterns of anatomical and behavioral changes seen between rat 
models and human patients with epilepsy in an effort to translate findings from basic research to 
the clinic. Researchers using animal models have reported permanent changes in brain circuitry 
after seizures (Mello et al., 1993), including cellular hyperexcitability and mossy fiber sprouting 
(for review see Dudak & Sutula, 2007). Another critical consequence of chronic uncontrollable 
seizures is neuronal loss. Humans with TLE show neuronal loss, sclerosis and atrophy, especially 
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in the hippocampus (Briellman et al., 2002). 
Animal models also report cell loss in various brain regions, especially in the limbic 
system (Borges et al., 2003; Mello et al., 1993).  Functional changes have also been reported in 
animal models, including changes in cognition and emotion after seizures (Borges et al., 2003).  
Different animal models of epilepsy exist, with two categories of models commonly 
utilized to emulate TLE. One of these categories involves the administration of chemical 
convulsants such as pilocarpine or kainic acid to induce an acute, severe excitotoxic episode 
characterized by status epilepticus (SE). In this model, the acute phase is approximated to be 24 
hrs and is followed by a latent phase lasting from 4 to 44 days and is characterized by the return 
to normal electroencephalogram (EEG) and no seizure-related behavior. Following this latent 
period is a chronic period of recurrent spontaneous seizures (Cavalheiro, 1995). The second 
approach is known as “kindling” in which frequent but small insults via chemical or electrical 
stimulation result in repeated seizures (Golarai et al., 1992). In this approach the animal develops 
chronic epilepsy without experiencing an acute episode of SE. Both models result in 
neuropathological and neurophysiological abnormalities that resemble those observed in human 
patients with epilepsy. However, these abnormalities are less extensive when using the kindling 
model. Abnormalities include neuronal loss, mossy fiber sprouting and synaptic reorganization 
in the hippocampus that favors hyper-excitability (Dudek et al., 2007). All of these abnormalities 
are thought to underlie the mechanisms of epileptogenesis (Wuarin & Dudek, 2001).    
In the pilocarpine model of TLE, pilocarpine acts on muscarinic receptors (Hedlund et. 
al., 1981) and its convulsant actions are often evoked in the presence of a peripherally acting 
muscarinic antagonist such as, methyl-scopolamine (Cavalheiro et. al., 2006) or atropine to limit 
peripheral cholinergic effects. This induction of SE by pilocarpine in rats lead to 
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neuropathological changes such as hippocampal sclerosis and mossy fiber sprouting that 
resemble human TLE. Therefore, among basic scientists, this model is representative of temporal 
lobe epilepsy precipitated by convulsive status epilepticus that has been well-characterized 
(Cavalheiro et al., 1991; Mello et al., 1993).  Experimental models of seizures and epilepsy are 
priceless tools in understanding the basic mechanisms underlying epileptogenesis.   
CNS Reorganization  
To begin to understand the basic mechanisms underlying seizure genesis and its resultant 
outcomes, it is important to distinguish between ictogenesis and epileptogenesis.  Ictogenesis, the 
induction of the seizure, is due to excessive discharges from groups of neurons, initiated by 
depolarized voltage-dependent sodium channels and activation of ionic glutamate receptors 
(Sasa, 2006).  Accordingly, the outcome or result of prolonged anatomical and biochemical 
alterations and “aberrant” reorganizations of neuronal networks that stem from repeated episodes 
of ictogenesis are known as epileptogenesis. It is well-known that epilepsy involves chronic 
excitoxicity and results in aberrant sprouting or the formation of more excitable neuronal 
pathways (Yang et al., 2003; Nobels, 2012)) suggesting refractory seizures may be due to 
reorganization that favors hyper-excitability following chronic injury or insult in the CNS. 
Reports have been controversial and the jury is still out as to whether these new synapses that 
form following SE are contributing to the epileptogenic pathway. Data from animal models 
suggest that these new synapses do indeed result in pathways that favor excitability (Buckmaster 
et al., 1997;Ben-Ari et al., 2006). Reports by Sutula and colleagues show that aberrant sprouting 
and new synapses form aberrant glutamatergic synapses (1988) and that this can be observed in 




In human patients with epileptogenesis it is difficult to know what came first, the seizure 
or the brain pathology. However, there are some neuroanatomical and neurophysiological 
similarities found among patients with chronic SE such as hippocampal sclerosis, reactive gliosis 
and astrocytic dysfunction, microvascular proliferation and synaptic organization (Matthern et 
al., 1997; Blumcke et al., 2002) as well as social, cognitive and emotional dysregulation or 
behavioral impairments (Briellmann et al., 2002; Yang et al., 2010). Pathology studies of human 
epilepsy tissue show reorganization that favors hyperexcitability, particularly in the dentate gyrus 
granule cells.  These changes include a loss of subgranular hilar interneurons, mossy cells and 
granule cells, and the development of mossy fiber sprouting, glial activation and neuronal loss. 
Evidence is accumulating supporting changes following chronic seizures or SE in many cell 
types. Although most reports in early work focused on neuronal loss and dysfunction, over the 
past few decades evidence from studies of other cell types is building and research is ongoing to 
reveal how they may be contributing not only to these neuronal changes (Seifert et al., 2006; 
Schroder et al., 2000; Wetherington et al., 2008) but also to the generation of the seizure itself 
(David, 2009).  One of the cell types that has been receiving the most attention in this regard is 
the astrocyte. 
Astrocytes in CNS  
Astrocytes are involved with information processing, synapse formation and clearance of 
extracellular neurotransmitters. Astrocytes serve many roles that include the uptake of 
potassium, water, glucose, and neurotransmitters (glutamate, GABA, glycine). Additionally, 
astrocytes release many substances such as nitric oxide (NO) and arachidonic acid (AA) 
associated with blood vessel regulation, lactate for energy, glutamate and precursors for 
glutamine neurotransmitters that help regulate neuronal excitability, purines, neurosteroids and 
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growth factors such as BDNF, VEGF, and TNF-α. Additionally, astrocytes secrete substances 
such as thrombospondin that are associated with synapse formation (Christopherson et al., 2005; 
Eroglu et al., 2009).  
Astrocytes have direct contact with blood vessels, neuronal synapses, and nodes of 
Ranvier.  They also have gap junctions with adjacent astrocytes and the ability to reach and 
service many neurons simultaneously. Evidence also exists that they have direct connection with 
neural progenitor cells (Vezzani et al., 2005). Astrocytes can stimulate neurite outgrowth and 
contribute to synaptic formation (Ullian et al., 2001). Therefore, astrocytes are not only 
important in ionic balance and metabolic action, but also in the control of balancing excitation 
and inhibition, modulating information processing, and the formation of synapses.  
Because of their broad interactions, astrocytes could be more intricately involved in 
functional and physiological abnormalities than previously suspected.  The heterogeneity of 
astrocytes and the high level of specificity in the connectivity of astrocytic networks make this 
role even more likely (Sul et al., 2004). In an interview with Maiken Nedergaard, attention is 
drawn to the much slower signaling of astrocytes when compared to neurons.  She proposes this 
may enable astrocytes to “process the information in a more sophisticated manner and retrieve 
memories” (Nedergaard & Oberheim, 2009). Based on their range of action, alterations of 
astrocyte morphology and function could lead to the memory impairment so typically observed 
in patients with epilepsy. However, in order for one to speculate about the astrocyte changes that 
may underlie dysfunction; one must first discuss the way these cells function under normal 
conditions. 
 In general, astrocytes are star-like cells with radially arranged processes. The cytoplasm 
of astrocytes contains intermediate filaments composed of a distinguishing protein glial fibrillary 
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acidic protein (GFAP) that is often used in studies to distinguish astroglia from neurons. The 
processes of astrocytes form an infrastructure that anchors all other CNS cell types.  The role of 
astrocytes as supportive to neurons was proposed by early neuroanatomists. However, the 
discovery of new techniques for visualizing glial cells has allowed us to better study how 
astrocytes function within the CNS. 
Astrocytes outnumber neurons in human brains over fivefold (Sofroniew & Vinters, 
2010) and form half of the human brain’s total volume. However, in rodents astrocytes 
outnumber neurons to a lesser extent and this ratio shift should be considered in animal models 
of neurological disease. Astrocytes also have interactions with endothelial cells and serve to 
maintain ionic balance (Sofroniew & Vinters, 2010; Abott et al., 2002) as well as support and 
play a role in the repair of the nervous tissue they are responsible for (Pekny et al., 2005; 
Sofroniew et al., 2005). Astrocytes have many ionic pumps including Na+K+, Na+Cl- and 
K+Cl- transport systems (Parent, A.1996) that help mediate their many functions within the 
CNS. Astrocytes undergo both cellular and molecular changes in epilepsy that include alterations 
in glutamate transporters, receptors, Kir channels and water channels.  
Sofroniew and colleagues (2005) report that the loss of CNS function after injury or 
insult, is ultimately due to neuronal loss or dysfunction. However, they propose that glial cells 
are primary responders to CNS insults and are therefore in a position to be key determinants of 
clinical outcome (Sofroniew, 2005). Reactive astrocytes are essential for both spatial and 
temporal regulation of inflammation after CNS injury (Bush et al., 1999; Hermann et al., 2007). 
Furthermore, Sofroniew and Vinters (2010) propose it is now clear that reactive gliosis occurs on 
a continuum of changes that are context-dependent and regulated by specific signaling events.   
 One role of astrocytes is as an important component of the “neurovascular units.” 
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Astrocytes, neurons, and microvessels form “neurovascular units” that together allow for the 
modulation and regulation of blood flow and nutrients to support normal communication in the 
CNS (Takano et al., 2006; Simard et al., 2004).  Astrocytic end feet form tight junctions around 
blood vessels and play a contributory role in the make-up of the BBB that serves many functions 
ranging from supply of nutrients to mediating the efflux of many waste products. Astrocyte 
processes also extend to the surface of the CNS to form the glial membrane beneath the Pia 
Mater. Astrocytes form the line that separates the brain from the mesenchymal structures that 
include capillaries, meninges and vascular adventitia.  
Functionally, astrocytes are broadly involved in the regulation of brain metabolism and 
function. Astrocytes have glycogen and activate glycogenolysis when neurons depolarize, 
suggesting a role for astrocytes to provide neurons with energy. Additionally, astrocytes release 
nitric oxide (NO) and arachidonic acid (AA) derivatives such as prostaglandins and leukotrienes 
and other vasorelaxing factors indicating they may play a role in vasodilation and constriction, 
respectively.  
Astrocytes also function to maintain adequate extracellular potassium and glutamate to 
control the microenvironment (Parpura & Haydon, 2009). The astrocyte membrane is more 
permeable to potassium than the neuronal membrane and astrocytes prevent increased 
extracellular potassium and spreading depression via “spatial buffering” and the astrocyte 
syncytium. Astrocytes also have a higher capacity for glutamate uptake when compared to 
neurons.  
Astrocytes can secrete extracellular matrix molecules and growth factors, which 
influence the survival of neurons and allow for both axonal and dendritic sprouting (Barres & 
Barde, 2000). Additionally, these cells promote synaptic formation, and maintain synaptic 
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function, which may actively modulate synaptic transmission via the glutamate-glutamine cycle 
(Pfrieger & Barres, 1996). Astrocytes may communicate with neurons via the release of 
gliotransmitters using a calcium-dependent mechanism. One important aspect to consider, in 
light of more recent work, is the growing information regarding astrocyte heterogeneity even 
within the same brain region.   
Types of Astrocytes 
In the CNS there are three types of astroglia: 1) fibrous, found mostly in white matter and 
possessing few organelles, 2) protoplasmic, possessing many organelles and generally located in 
the gray matter, and 3) radial, located at the interface between gray matter and the pia mater. It is 
important to consider these subtypes when speculating about the function of astrocytes in the 
CNS. Differing astroglia subtypes are associated with differing responses and therefore may play 
different roles within the CNS.  
Astrocytes display a high degree of phenotypic plasticity since they respond to various 
stimuli via change of form, function, and rate of multiplication (Parent, A., 1996). According to 
work by Barres and colleagues over the past decade or so, the largely specified gene expression 
profiles of astrocytes (Cahoy et al., 2008; Doyle et al., 2008) speaks to the functional diversity of 
these cells and hence their interactions with other cell types and ultimately in their contribution 
in the metabolism of neurotransmitters that are so crucial in epilepsy (Zhang & Barres, 2010). 
Future studies are ongoing in an attempt to provide information regarding the distinct role or 
various roles each astrocyte subtype may play as well as any findings that may reveal 
information regarding astrocyte differentiation or de-differentiation that may occur in response to 
specific types of insults or in particularly crucial regions of the CNS. It has been demonstrated 
that the heterogeneity of astroglia must be considered due to recent findings that cells with 
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astroglial properties can express glutamate transporters but ionotrophic receptors (classic 
astroglia) while other subsets express ionotrophic receptors but not glutamate transporters and 
are known as NG2 glia or GluR cells (Matthias et al., 2003; Nishiyama et al., 2005). Studies 
show that NG2 cells lack gap junction coupling but receive direct synaptic input from 
GABAergic and glutamatergic neurons (Lin & Bergles, 2004; Wallraff et al., 2004; Jabs et al., 
2005).  Zhou and colleagues suggest that NG2 cells are another subtype of astrocytes and should 
no longer be classified under “complex” astroglia (2006).  
Astrocytes & seizure 
Astrocytes in the “normal” brain have a domain organization that is spatially non-
overlapping. However, with chronic seizures, the hippocampal astrocytic domain organization is 
altered such that astrocytic processes are overlapping at a rate of approximately an 8-15 fold 
increase in a rodent model. This loss of domain organization is prevented or reduced in seizure 
patients receiving typical pharmacological treatments (Oberheim et al., 2008).  Morphological 
changes in astrocytes were accompanied by neuronal changes such as hypertrophy of apical 
dendrites and increased spine density, suggesting that these changes are associated with the 
development of recurrent excitotoxicity. Findings suggest that reactive astrocytes exert both pro 
and anti-inflammatory functions dependent upon the location and timeframe investigated in 
response to injury and during repair (Bush et al., 1999; Faulkner & Hermann, 2004). Bush and 
colleagues report that the ablation of reactive astrocytes following experimental brain injury 
results in massive tissue edema in the local tissue, suggesting that reactive astrocytes may help 
regulate tissue fluid levels and toxic edema will result if astrocytes lose the ability to perform this 
important function. Furthermore, NMDAr antagonists attenuate neuronal death, suggesting that 
astrocyte loss results in accumulation of extracellular glutamate and leads to excitotoxicity of 
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both neurons and oligodendrocytes (Bush et al., 1999). This ides is consistent with the findings 
of Rothstein’s group, who report that deletion of genes encoding astrocyte specific glutamate 
transporters exacerbates glutamate receptor-mediated excitotoxicity (1996). Astrocytes also have 
the ability to release glutamate, which could induce an imbalance of excitation and inhibition in 
the local circuit, and could influence epileptiform events such as the paroxysmal depolarizing 
shift (PDS) (Nedergaard et al, 2005).  
 Astrocytes may wield non-stereotyped bimodal synaptic control via release of 
gliotransmitters such as purine, which imparts inhibitory control, and glutamate, which imparts 
stimulatory control (Volterra & Meldolesi, 2005). Some work is shedding light on subtypes of 
astrocytes and proposes those with presence of AMPA Glu receptors do not have glutamate 
transporters; whereas another subtype contains glutamate transporters but not glutamate 
receptors and have extensive gap junction coupling (Mathias, 2003). This work suggests the 
presence of GluR cells that appear identical to NG2 cells but have increased Ca++ oscillations 
and can be depolarized to release action potential like responses. GluT cells are reported as 
almost completely lost in sclerotic tissue, suggesting that only GluR cells remain, potentially 
leading to the increased glutamate and extracellular potassium that result in excitotoxicity. Given 
that both of these gliotransmitters have various receptor targets on both excitatory and inhibitory 
neurons, and that astrocytes also release other gliotransmitters, the complexity may be difficult to 
decipher without further understanding the distinct roles these various subtypes of astrocytes 
may play and how they respond to typical conditions of excitotoxicity.  
The loss of astrocytes following CNS injury early on may lead to secondary degeneration 
of other cell types (Liu et al., 1999; Zhao et al., 2003). Reactive astrocytes express fibronectin 
and can support the regrowth of certain types of CNS axons along their cell surface (Gage et al.,, 
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1988; Tom et al., 2004), so their loss could impede these processes.  
   Astrocytes show many changes in human epilepsy and reports include the expression of 
specific glutamate receptors, redistribution of AQP4, increase sodium and calcium channels as 
well as decrease in Kir 4 1 channels (Nobels et al., 2012). This group also reports reduction in 
GS and lactate dehydrogenase and some increase in immune molecules. It is necessary to 
recognize that astrocytes with these changes can be categorized into subtypes that should be 
considered in future studies. Findings suggest sclerotic tissue cells may have cells capable of 
Ca++-dependent excitotoxic glutamate release and swelling resultant of APQ4 changes may also 
facilitate astrocytic release of glutamate and will lead to alteration of Kir channels. One 
consistent finding of astrocytic alteration that is reported is reactive gliosis and has become a 
marker for astrocytes under pathological conditions (Sofroniew et al., 2010). 
Reactive Astrocytes 
Astrocytes respond or become reactive in response to many forms of CNS insults through 
a process known as reactive gliosis. The extent of reactive gliosis and its duration is dependent 
upon the type and severity of the insult (Pekny & Pekna, 2004). Reactive gliosis marks 
pathological tissue according to the literature (Sofroniew, 2009) and signs of CNS regeneration 
become more prominent in experiments that report the effects of attenuating reactive gliosis 
long-term (Pekny et al., 2004; 2005) More recently, Pekny and colleagues have reported that 
reactive gliosis is accompanied by the altered expression of many genes. In this same article they 
propose that reactive gliosis immediately following an insult may serve a neuroprotective role, 
but at later stages reactive gliosis may facilitate the formation of a glial scar that inhibits synaptic 
formation and compromises neural graft survival and integration. 
Reactive astrocytes show changes in regulatory functions in various channels that may 
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exacerbate dysregulation of the microenvironment if persistent for long periods. However, 
reports are inconsistent and do not provide a clear picture of this phenomenon. One view is that 
astrocytic gliosis leads to glial scarring and therefore prevents axonal regeneration in the CNS. In 
contrast, many reports have established that one benefit of glial scarring is the demarcation of 
damaged tissue and the decreased spread of the inflammation response to adjacent tissues 
(Sofroniew, 2005). IL-1β, a potent pro-inflammatory cytokine, is upregulated during 
epileptogenesis in astrocytes but not microglia, suggesting a prominent role of astrocytes in 
sustaining chronic inflammation before the onset of spontaneous seizures (Ravizza, 2008). 
However, reactive gliosis at later time points, following injury or insult, may be more 
detrimental than beneficial.  The findings of Lider and colleagues (1995) suggest that reactive 
gliosis leading to inhibition of axon regeneration may be a byproduct of the redundancy of 
migratory guidance cues among and between the cell types speaking to the importance of 
attenuating reactive gliosis beyond the necessity to prevent inflammatory spreading to adjacent 
tissue following insult or injury. Liberto and colleagues (2004) report the contrasting view that 
cytokines activate astrocytes and that this activation can promote the recovery of the CNS 
function.  
Astrocytes have been shown to secrete extracellular matrix molecules and growth factors 
that influence the survival of neurons (Barres & Barde, 2000), can promote synaptic formation 
and maintain synaptic function via glutamate uptake (Pfrieger & Barres, 1996). In particular, 
animal models of neurological disease demonstrate a change in levels of astrocyte-secreted 
thrombospondin that appears to be involved with synapse formation. Thrombospondin proteins 
such as thrombospondin-1 (TSP1) and TSP2 are produced by astrocytes and contribute to the 
development of synapse formation and neural plasticity. Garcia and colleagues (2010) reported 
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that knockout mice or depletion of TSP1 resulted in changes in spine morphology, while 
restoration of TSP1 prevented these alterations. Recently it was demonstrated that TSP1 is 
necessary for synaptic and motor recovery after stroke (Liauw, 2008) suggesting that this plays a 
role in neural plasticity.  
Another important function of astroglial activation is growth factor release. One such 
growth factor is vascular endothelial growth factor (VEGF), which has been implicated in 
neuroprotection. Astrocytes have themselves been shown to be VEGF responsive (Croll et al., 
2004; Ackerman et al., 2003; Mani et al., 2005).  Since VEGF has been shown to protect neurons 
from excitotoxicity (Nicoletti et al., 2008; Matsuzaki et al., 2001), there is reason to speculate 
that it plays a role in the protection of astrocyte organization as well. Given that glial cells have 
been reported to express VEGF receptors both constitutively (Krum & Rosenstein, 2004) and 
after seizures (Nicoletti et al., 2008), it is possible for VEGF to impact their function or 
morphology.  
Astrocyte Signaling in Epilepsy 
 More and more evidence is developing that points to the contribution of glial cells to 
epilepsy and other CNS disorders (Steinhauser & Seifert, 2012; Aronica et al., 2012; Oberheim 
et al., 2008; Tian et al., 2005; Kang et al., 2005). Glial cells in epilepsy show redistribution of 
glutamate receptors, AQP4, increase in Na+ and Ca++ channels and decreased Kir channel 
activation. Enzyme changes such as reductions in glutamine synthetase (GS) and lactate 
dehydrogensase also occur. In addition, immune molecules are increased in astrocytes studies in 
epileptic brains (Nobels, 2012).  
 Early work established astrocytes to be crucial in maintaining the balance of the 
extracellular environment; specifically in limiting K+ and glutamate (Kuffler & Potter, 1964; 
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Newman, 1984).  Astrocytic “spatial buffering” and the knowledge that extracellular potassium 
influences excitability, has driven a surge in research that reveals interesting information and 
proposes an astrocytic basis of epilepsy. Wallraff and colleagues (2006) report that astrocytic, 
not neuronal, inward-rectifying K+ channels are indicated in downregulation of Kir channels and 
reduced spatial buffering. Yaron David and colleagues (2009) used a NEURON model to 
assimilate the reduced uptake of potassium and glutamate on EPSPs and results showed an 
accumulation of glutamate to be associated with frequency-dependent decreased facilitation of 
EPSPs.  In addition, potassium accumulation leads to frequency-dependent NMDA-dependent 
synaptic facilitation, a phenomenon that electrophysiological recordings have confirmed can lead 
to seizure-like activity.   
 It has been demonstrated that changes in expression, localization and function of the 
Kir4.1 inward-rectifying potassium channel are reported in astrocytes in neurological disorders, 
particularly in TLE (Olsen & Sontheimer, 2008). Additionally, attention has been focusing on 
the role of Kir channels in cell division and Olsen’s group proposes that loss of Kir4.1 may 
underlie the re-entry of glial cells into the cell cycle supporting gliosis (2008). Gliosis is 
observed after most traumatic insults to the brain, including after status epilepticus.  Blood-brain 
barrier is also perturbed after status, which can lead to the leak of blood proteins into the brain.  
Interestingly, albumin uptake into astrocytes is mediated by TGF-ß, which produces the 
downregulation of Kir4.1 in astrocytes (Ivens et al., 2007).  Kir4.1 expression is also influenced 
by extracellular changes in other inflammatory cytokines such as IL-1ß (Zhang et al., 2011), 
which are also upregulated after status.  As further evidence of a possible role of astrocyte 
signaling in epilepsy, deletion of the Kir4.1 gene in mice leads to inhibition of K+ and glutamate 
uptake, hyperexcitability and seizures (Djukic et al., 2007). Mutations in the human Kir4.1 gene 
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are also associated with epilepsy, suggesting a role for astrocytic potassium channels in human 
epilepsy (Olsen & Sontheimer, 2008; Chevor et al., 2010; Zhang et al., 2011).  
 Astrocytes have been experimentally shown to contribute to epileptiform discharges in 
the hippocampus (Kang et al., 1998; Tian et al., 2005). With chronic seizures, the hippocampal 
astrocytic domain organization is altered such that astrocytic processes are overlapping at a rate 
of approximately an 8-15 fold increase in a rodent model. This loss of domain organization is 
prevented or reduced in seizure patients receiving typical pharmacological treatments (Oberheim 
et al., 2008).  Morphological changes in astrocytes were accompanied by neuronal changes such 
as hypertrophy of apical dendrites and increased spine density, suggesting these changes could 
form the foundation for recurrent excitotoxicity. In addition, it has been demonstrated that 
increased astrocytic Ca++ signals play a role in neuronal excitotoxicity after status epilepticus 
and that these signals were capable of inducing the release of glutamate which may contribute to 
delayed neuronal death and later cognitive decline (Ding et al., 2007). Others have made similar 
conclusions from their results that delayed neuronal death led to cognitive decline and later 
epilepsy (Lemos & Cavalheiro, 1995).  
 Finally, astrocytes are responsible for glutamate-glutamine cycling and are key players in 
maintaining a balance between excitation and inhibition.  Imbalance in these processes is a 
primary problem in seizures and likely contributes to epileptogenesis.  Astrocytes use their 
glutamate transporters, Glt-1, to internalize excess glutamate in the synapse, and then use the 
enzymes glutamine synthetase and glutaminase to convert glutamate to glutamine.  Astroglia are 
responsible for 90% of glutamate clearance and regulation of extracellular glutamate levels 
(Behrens et al., 2002; Bacci et al., 2002). Glutamine synthetase (GS) and glutaminase are 
downregulated in epileptogenesis (Derouiche & Frotscher, 1991), providing further evidence for 
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dysregulated astrocyte glutamate processing in epilepsy.  
Astrocytes and Inflammation after Seizures  
 Astrocyte activation, like microglia activation, is a common component of brain 
inflammatory responses, including those inflammatory responses observed after seizures. When 
activated, glia can release pro-inflammatory cytokines.  Elevations in these cytokines have been 
reported in human patients and in experimental models of epilepsy (Vezzani et al., 2008; 
Jankowsky & Patterson, 2001).  Indeed, genetic susceptibility to inflammation appears to 
positively correlate with risk for epilepsy, perhaps particularly in childhood epilepsies (Choi & 
Koh, 2008).  A rapid onset of inflammatory responses in glia is triggered by seizures (DeSimoni, 
2000). It is well documented that chronic seizure activity results in cellular and molecular 
changes to both neurons and glial cells. More recent reports are adding to the role of brain 
inflammation in epileptogenesis (Kleen & Holmes, 2008). Immune-mediated damage to the CNS 
is reported to contribute to epileptogenesis both directly through inflammation and indirectly by 
causing BBB leakage (Choi et al., 2008; Croll et al., 2004). One study by Seiffert and colleagues 
showed problems with opening of the blood brain barrier (BBB) after a latency of 4 days and 
lasting up to 49 days and suggests this opening in the BBB may be epileptogenic and very 
important in the development of seizure disorders.  Although the mechanisms of BBB opening 
during inflammation are unproven, multiple cell types in the brain have the ability to upregulate 
and release VEGF, a potent vascular permeability factor (Senger et al., 1986).  Upregulation of 
VEGF by both neurons and astrocytes is marked after status epilepticus (Nicoletti et al., 2008), 






Vascular endothelial growth factor (VEGF) is a protein mitogen originally discovered for 
its potent effects on vasculature (Senger, 1986).  In spite of its vascular permeabilizing effects, 
VEGF has been more recently investigated for its neurotrophic effects (for review see Carmeliet 
& Storkebaum, 2002). Studies have shown that VEGF protects neurons in culture from a variety 
of insults, including hypoxia, ischemia, and excitotoxicity (Jin et al., 2000, 2001; Matsuzaki et 
al., 2001) and has been shown to protect against ischemic neuronal damage in vivo (Wang et al., 
2005; Bellomo et al., 2003; Sun et al., 2003; Hayashi et al., 1998).  VEGF may play a role in 
protecting neurons against neurodegenerative processes as is demonstrated in amyotrophic lateral 
sclerosis (Storkebaum & Carmeliet, 2004; Zheng et al., 2004), Parkinson’s disease (Falk et al., 
2010), and epilepsy (Nicoletti et al., 2008). 
The VEGF Family 
In order to elucidate VEGF’s role in epilepsy, it is important to understand how VEGF is 
produced endogenously.  The human VEGF gene is located on chromosome 6p21.3 and is 
composed of 8 exons separated by 7 introns with a coding region of approximately 14kb 
(Vincenti et al., 1996).  The promoter region is located near a cluster of potential binding sites 
for Sp1, AP-1, and AP-2 transcriptional factors.  These transcription factors regulate gene 
expression and are involved in a number of cellular processes such as apoptosis, differentiation 
and proliferation. Through alternate exon splicing, the VEGF gene codes for several isoforms of 
VEGF, such as 121, 145, 165, 183, 189, and 206, each composed of a specific number of amino 
acids (Tischer et al., 1991).  Each VEGF isoform differs in its expression pattern and biological 
properties.  The murine VEGF gene is similar to the human VEGF gene with 8 exons divided by 
7 introns encompassing 14kb, however, this gene only codes for 3 isoforms, 120, 164, and 188, 
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which are shorter than human VEGF by one amino acid (for review, see Ferrara & Davis-Smyth, 
1997).  Because our experiments were conducted in rat, it is important to understand the 
biophysical characteristics of human and murine isoforms.     
VEGF121, VEGF165, and VEGF189 are the most commonly expressed forms of VEGF and 
have been found in a wide range of tissues while VEGF145 and VEGF206 are relatively rare and 
limited to cells of placental origin (Robinson & Stringer, 2001).  VEGF183 has recently been 
identified and is a less frequent splice variant.  All isoforms bind heparin except VEGF121, which 
is released as a freely soluble protein.  VEGF189 and VEGF206 bind to heparin with high affinity 
and are almost completely sequestered in the extracellular matrix after secretion (Zachary & 
Gliki, 2001).  VEGF165, which is the major isoform found in most mammalian tissue, is secreted 
as a 46,000 dalton heparin-binding homodimeric glycoprotein.  Its intermediate affinity for 
heparin results in a significant portion remaining bound to the extracellular matrix and cell 
surface (Robinson & Stringer, 2001).  It has been demonstrated that VEGF protein becomes 
available to endothelial cells as freely diffusible proteins, as is the case with VEGF121 and 
VEGF165, or it must be cleaved by plasmin at the COOH terminus, as is the case with the longer 
forms bound in the extracellular matrix (Keyt et al., 1996).  While there is an inverse relationship 
between heparin affinity and diffusibility, there is a direct relation between the affinity of each 
isoform for heparin-binding and its mitogenic activity.  Typically, those with a higher affinity for 
heparin exhibit greater mitogenic activity for vascular endothelial cells although this is not 





VEGF121 VEGF165 VEGF189 
Heparin Affinity + ++ ++++ 
Diffusibility ++++ +++ + 
Mitogenic Activity ++ ++++ + 
 
Table 1.  Major VEGF isoforms and their properties (adapted from Ferrara, 2001).  It appears 
that VEGF165 has the greatest bioavailability combined with biological potency. 
VEGF Family and Receptors 
 The VEGF family of growth factors bind with high affinity to three receptor tyrosine 
kinases (RTKs),: VEGFR1 also known as Flt1, VEGFR2 also known as Flk1 or KDR, and 
VEGFR3 also known as Flt4,.  In addition, they bind to the non-catalytic receptor family, the 
neuropilins (Soker et al., 1998; Neufeld et al., 1999; Glutzman-Poltorak et al., 2001). The 
VEGFR family of tyrosine kinase receptors triggers the activation of signaling pathways such as 
the Erk/MAPk pathway or the Akt pathway (Gerber et al., 1998). VEGFR3 is not found in brain, 
and is therefore unlikely to contribute to VEGF's CNS effects. When VEGF binds VEGFR1 and 
VEGFR2 in the brain, these receptors dimerize. This causes the RTKs cytoplasmic tyrosine 
kinase domain to autophosphorylate, triggering an intracellular signaling cascade that transduces 
the original signal of VEGF binding into the cell. VEGFA, the most abundant VEGF family 
member, binds to both VEGFR1 and VEGFR2. Reports demonstrate that both VEGFR1 and 
VEGFR2 are expressed on neurons and glial cells (Krum et al., 2002), and that both RTKs are 
densely localized to hippocampus. However, it is important to recognize that VEGFR1 has been 
reported to gradually decrease during development whereas VEGFR2 increases gradually and is 
observed at its highest numbers in the adult brain in the hippocampus (Yang et al., 2003). Falk 
24 
 
and colleagues (2010) reported that mice with genetic deletion of VEGFR1 die from abnormal 
vascular development, the pattern of which suggested that VEGFR1 may regulate VEGFR2 
activation by serving as a decoy receptor.  
 Many studies implicate VEGFR2 as the more likely pathway to neuroprotection. For 
instance, Cao and colleagues (2004) propose that VEGFR1 could be ruled out as responsible for 
a reduction in excitability due to the observation that VEGFR1 produces a decreased potassium 
current and a decrease in the delayed rectifier after exposure to VEGF and would therefore lead 
to an increased rather than a decreased excitability (Cao et al., 2004).  VEGFR1 is upregulated in 
reactive astrocytes, and blockade of VEGFR1 reduces astroglial mitogenicity, scar formation, 
and expression of growth factors (CGF & FGF).   Blockade of VEGFR2 reduced vascular 
proliferation around a brain wound site and increased endothelial degeneration without effects on 
astrogliosis or growth factor expression (Harris A., 2002) suggesting that VEGF may induce 
angiogenesis, astroglial proliferation and expression of growth factors via VEGFR1. This idea is 
also supported by results of exogenous VEGF administrated in TBI (Thau-Zuchman et al., 2010). 
 Differential binging to VEGFR1 versus VEGFR2 is not responsible for all of the 
variability in the effects of VEGF in the brain. VEGF's non-catalytic co-receptors, the 
neuropilins, are highly localized to brain and have been shown to modulate the effects of VEGF 
binding at its RTKs (Chedotal et al., 1998).  The neuropilins include neuropilin 1 and neuropilin 
2 (NRP1 &2). Neuropilin 1 (NRP1) is expressed by both endothelial cells and neurons and 
serves as a receptor for both VEGF and Semaphorin 3A (Sema 3A), an inhibitory mediator of 
axonal guidance. They neuropilins were first identified through their key role in mediating 
axonal guidance via interactions with semaphorins in the developing nervous system (Yang et 
al., 2004). Studies have demonstrated that Sema3A, Sema3B and Sema3F compete with VEGF 
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for neuropilin binding (Miao et al., 1999) and that soluble NRP1 may act as a VEGF antagonist 
(Gagnon et al., 2000). Downregulation of NRP1 by NRSF overexpression reduced Sema3A 
activity (Kurschatt et al., 2006). One translation research study reported pilocarpine increases 
NRSF but if block NRSF from binding attenuates epileptogenesis (McClelland et al., 2011). 
Neuropilin 2 also binds semaphorins but Sema3E and Sema IV but not III. NPR2 is reported to 
selectively mediate repulsive guidance events in discrete neuron populations during neural 
development (Giger et al., 1998). Together this suggests that these co-receptors and their 
affinities may reveal important information regarding structural basis of receptor function and 
specificity (Giger et al., 1998). Soker and colleagues demonstrated that NRP1 enhanced the 
binding of VEGF to VEGFR2 (2002). VEGFA binds both NRP1 and 2; whereas VEGFB and 
PlGF only bind NRP1.  
 
Figure 1.  The VEGF family members, their receptors, the receptor tyrosine kinases VEGR-1, 
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VEGFR-2, and VEGFR-3 and co-receptors Neuropilin-1 and Neuropilin-2 (adapted from Croll et 
al., 2006).  
VEGF Regulation 
Several variables appear to play a role in the expression of the VEGF gene.  Reports have 
demonstrated that activity of the mTORC pathway leads to VEGF upregulation (Elving et al., 
2012). One key contributor to VEGF expression is hypoxia. Hypoxic conditions result in the 
binding of hypoxia-inducible factors (HIFs) to the hypoxia response element (HRE) where the 
promoter region of the VEGF gene is located (Carmeliet et al., 1998; Marti & Risau, 1998).  The 
ability of HIFs to upregulate VEGF appears adaptive under hypoxic conditions as VEGF serves 
to increase vasculature in the hypoxic region that increases the amount of oxygen and nutrients 
delivered to metabolically-compromised neurons.  In the context of seizures, cells become more 
metabolically active, and as their need for glucose and oxygen increases they may experience a 
“relative” state of hypoxia.  These hypoxic conditions may lead to VEGF upregulation in an 
effort to preserve cells during seizures.   
VEGF and Epilepsy 
Both VEGFA and VEGFB have been shown to be upregulated in patients with intractable 
epilepsy but VEGFA is upregulated in both neurons and astrocytes; whereas VEGFB is only 
upregulated in neurons.  Work from our own laboratory has demonstrated that VEGFA is also 
upregulated in animal models of epilepsy (Nicoletti et al., 2008).  Mice that overexpress 
VEGFR2 upregulate VEGF in neurons and glia after seizure relative to wild type mice, and these 
mice also show less seizure-induced neurodegeneration in vivo, accompanied by an increase in 
seizure threshold and decrease the duration of focal after discharges suggesting an anti-ictal 
effect (Litsa Nikitidou et al., 2012). Furthermore this group found no significant effects on blood 
27 
 
vessels or glia suggesting increased VEGF signaling in VEGFR2 overexpressing mice may 
directly affect seizure activity without altering angiogenesis.  
 We have previously reported that VEGF protein is not only strikingly increased in both 
neurons and glial cells following pilocarpine-induced status epilepticus, but is also 
neuroprotective against status epilepticus-induced neuronal loss in the hippocampus when 
measured 24 hours following the  seizure induction (Nicoletti et al., 2008).  A recent review by 
Ann Marie Vezzani (2005) proposed that not only does VEGF produce neurogenic effects that 
affect neuronal function; but that the mechanism of this phenomenon may be due to VEGF’s 
effects on neuronal progenitors.  
In addition to effects on neurons, VEGF effects, at least in part, may have an astrocytic 
basis as opposed to or in conjunction with a neuronal one. Interestingly, reports have been 
published showing astroglia to both have VEGF receptors (Krum & Rosenstein, 2002) and be 
VEGF responsive (Ackerman et al., 2003; Croll et al., 2004; Mani et al., 2010). Additionally, 
Croll and colleagues reported the expression of VEGF shows a pattern of immunoreactivity that 
envelops glial-like cells (Croll et al., 2004). McCloskey and colleagues (2005) found that VEGF 
treatment reduced hyperexcitability without altering neuronal membrane properties suggesting 
that non-neuronal mechanisms, such as those mediated by astrocytes, cannot be ruled out.  
Specific Aims 
 The goal of this dissertation was to study astrocyte morphology and astrocyte glutamate 
transporter expression following VEGF administration within the context of pilocarpine-induced 
status epilepticus (SE), to determine VEGF's effects on astrocytes in this context. Our primary 
objective was to better understand changes in astrocyte morphology that could reflect beneficial 
changes in astrocyte function contributing to the protective effects of VEGF on hippocampal 
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Specific Aim 1: To determine whether VEGF administration during status epilepticus 
alters long-term astrocyte patterning or the inter-astrocyte distance in the rat 
hippocampus. 
To investigate inter-astrocyte distances, neighboring astrocytes were measured from soma center 
to soma center in tissue stained with the astrocyte marker GFAP. Astrocytes from rats receiving 
exogenous VEGF in the dorsal hippocampus were compared to those receiving inactivated 
VEGF in both pilocarpine-treated and saline-treated animals. 
Specific Aim 2:  To determine whether administration of VEGF during status epilepticus 
alters the long-term morphology of astrocytes in the dorsal hippocampus after status 
epilepticus in rats using a branched structure analysis.  
To investigate astrocytic morphological changes that occur following status epilepticus in 
animals receiving VEGF protein versus those receiving inactivated VEGF control, hippocampal 
astrocytes were traced and reconstructed using Neurolucida software (Microbrightfield, Inc.). 
More specifically, any changes such as branch structure, branch order, diameter of processes, 
length of processes, astrocyte surface volume, mean tortuosity, aspect ratio and roundness were 
measured by performing Branched Structure Analysis using the Neuroexplorer software program 
(MicroBrightfield, Inc.) Astrocytes from rats receiving exogenous VEGF into the dorsal 
hippocampus were compared with those receiving inactivated VEGF in both pilocarpine-treated 
(experimental condition) and saline-treated (control condition) rats.  
Specific Aim 3:  To determine whether administration of VEGF during status epilepticus 
alters the long-term morphology of astrocytes in the dorsal hippocampus after status 
epilepticus in rats using Sholl analysis.  
To investigate astrocytic morphological changes that occur following status epilepticus in 
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animals receiving VEGF protein versus those receiving inactivated VEGF control, hippocampal 
astrocytes were traced and reconstructed using Neurolucida software (Microbrightfield, Inc.). 
More specifically, any changes in the number of intersections and the length of the processes at a 
distance of 5 mm increments moving away from the soma were measured using a Sholl Analysis 
and the Neuroexplorer software program (MicroBrightfield, Inc.) Astrocytes from rats receiving 
exogenous VEGF into the dorsal hippocampus were compared with those receiving inactivated 
VEGF in both pilocarpine-treated (experimental condition) and saline-treated (control condition) 
rats.  
Specific Aim 4:  To determine whether administration of VEGF during status epilepticus 
alters long-term astrocyte glutamate transporter levels or patterns of expression in the rat 
hippocampus with or without status epilepticus.  
 To investigate potential alterations in glutamate transporter expression in the 
hippocampus of rats receiving VEGF or inactivated VEGF during and following status 
epilepticus that could indicate altered capacity for glutamate uptake/reuptake, which could 
impact hippocampal circuit excitability. Immunohistochemical staining for glutamate 
transporters were conducted followed by quantitative analysis to investigate the relative density 
and compartmentalization of glutamate transporters. 
Specific Aim 5 –To determine whether any of the alterations observed in astrocytes treated 
with VEGF during status epilepticus were predictive of hippocampal function as evaluated 
by behavioral tests of hippocampally-mediated cognition. 
 To determine whether changes in astrocyte morphology was predictive of behavioral 
function, animals were studied in three behavioral tests were conducted 2-4 weeks after SE. A 
Morris Water Maze was used to measure hippocampally-mediated learning and memory, a 
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light/dark exploration task as a measure of anxiety, and a grid locomotor task was used to 
measure locomotor and exploratory drive. Behavioral data were then regressed against the 
topological and metric measures from the branched structure analysis and Sholl analyses to 
determine whether any of these astrocyte measures were significantly predictive of behavioral 





Chapter 2: Methods & Results 
 




All subjects were adult male Sprague Dawley rats (Charles River, Laboratories, 
Kingston, NY, USA) weighing 350-450 grams.  Animals were housed 3 per cage within a 
temperature controlled facility with food and water available ad libitum. All animals were 
maintained on a 12 hr. light-dark cycle. All experiments were approved by the Queens College 
Institutional Animal Care and Use Committee which operates under federal and state animal care 
guidelines. All experiments conformed to international guidelines on the ethical use of animals 
and every effort was made to minimize the number of animals used and to maximize their 
comfort. Male Sprague Dawley rats were used because of the strong history of use of this model 
in this strain and the desire to use an outbred strain. 
Proteins 
 The VEGF administered for protein infusions was human recombinant VEGFA165 
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(generous gift of Regeneron Pharmaceuticals, Tarrytown, NY, USA). VEGF was kept frozen (at 
-80°C) until use and was then thawed and diluted in sterile phosphate-buffered solution (PBS) 
(Sigma-Aldrich, St. Lois, MO, USA) to attain a dosage of 45 ng per day infused at a rate of 0.5 
µl per hr. delivered via a two-week osmotic mini-pump (Alzet Model 2002; Durect Corporation 
Cupertino, CA). This dose was selected based on previous dose curve studies within our lab that 
showed 15ng per day or lower to have no effect and 60 ng per day or more to sometimes result in 
overt angiogenesis in the brain when using human VEGFA 165 (Nicoletti et al., 2008). 
Inactivated VEGF was used as the control protein (inactivated by repeated freeze-thaw cycles) 
and PBS was mixed from powder form and sterilized in the autoclave before use. Protein 
reagents were continuously infused into the dorsal hippocampi starting 5 days before pilocarpine 
seizure induction and continuing for 2 weeks. 
Cannula and pump implantation for protein infusions 
 Animals receiving protein infusions, whether active or inactive VEGF protein, were 
anesthetized using 1mg/kg of sodium pentobarbital (Sigma-Aldrich) delivered via intra-
peritoneal injections. Cannula implantation surgeries were performed by first shaving the scalp 
and neck area and applying alcohol to clean the incision site and then betadine iodine solution to 
create a barrier against infection. Animals were placed into a stereotaxic apparatus and a 
longitudinal incision was made along the scalp.  Burr holes were drilled into the skull using a 
Dremel drill and three anchor screws were inserted to provide stability to the skull cap. Two 
sterile cannula, 4mm in length, each with an attached heat-sealed polyvinyl catheter tube 
(Plastics One, Roanoke, VA, USA) containing sterile PBS were implanted bilaterally into the 
dentate gyrus of the dorsal hippocampi at coordinates AP -3.8 and ML -/+2.7 measured from 
bregma. This location was based on previous findings that VEGF diffuses over a 3mm diameter 
(Croll et al., 2004b) allowing for diffusion of VEGF throughout most of the dorsal hippocampus. 
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A dental acrylic mixture was then applied to secure the cannula to the anchor screws, forming a 
stable skull cap. The surgical incision was then closed using nylon sutures, topical antibiotic 
cream was applied, and animals were placed under a heat lamp to recover. 
 Animals were given one week for surgical recovery and then pump implantation 
surgeries were performed. Animals were re-anesthetized in a chamber filled with an isoflurane-
oxygen mixture and placed into a nose cone delivering 2.5-3% isoflurane in 100% oxygen for the 
duration of the pump implantation surgery. An incision was made at the nape of the neck, at 
which time both catheter tubes were located.  The heat-sealed tips were cut off the catheters and 
Alzet osmotic minipumps (Durect Corporation, Palo Alto, CA, USA) filled with either active or 
inactivated (freeze-thawed several times) rhVEGFA 165 (Regeneron Pharmaceuticals, 
Tarrytown, NY) were glued onto the catheters with cyanoacrylate glue.  VEGF was delivered at 
45ng per day at 0.5 µl per hour for two weeks. The pump was inserted into a subcutaneous 
pocket at the nape of the neck, the incision was closed using nylon sutures, topical antibiotic 
cream was applied, and animals were placed under a heat lamp to recover. 
 




Non-Seized N=3 N=3 
Pilocarpine-induced SE N=5 N=5 
 
Table 2. Shows the experimental design including the four group conditions and number of 
animals in each condition. Each animal was then represented by multiple parameters quantified 
in eight astrocytes from the CA1 region and 10 astrocytes from the dentate gyrus region relevant 




Acute seizure induction 
 Exactly five days following pump implantations for protein infusions, animals were given 
subcutaneous injections of atropine methyl bromide (1mg/kg) 30 minutes prior to intraperitoneal 
injections of pilocarpine hydrochloride at 350 mg/kg (Sigma-Aldrich).  The atropine was 
administered before the pilocarpine to prevent any systemic cholinergic effects of the pilocarpine 
such as excessive saliva production. Seizures were scored using a modified Racine scale (1972) 
in which stages 1-4 were identical to the originally published Racine scale but stage 5 was 
defined as transient whole body tonus, stage 6 was status epilepticus (SE), stage 7 was SE with 
prolonged tonus, and stage 8 was seizure-related death (modified scale published in Rudge et al., 
1998). 
Status epilepticus was truncated at one hour with 10mg/kg of diazepam (Henry Schein, 
Melville, NY, USA) given intraperitoneally (i.p.). Animals that did not reach SE were given 
10mg/kg of diazepam intraperitoneally one and a half hours after the pilocarpine hydrochloride 
injection. Animals not reaching SE were excluded from all histological analyses.  Control 
(unseized) animals received both a pre-treatment subcutaneous injection of atropine and an i.p. 
injection of diazepam one and half hours following the vehicle (PBS) injection given in place of 
the pilocarpine hydrochloride.  
Fixed Tissue Collection for Histology   
Animals were deeply anesthetized 4 weeks after the seizure inductions and transcardially 
exsanguinated with heparinized saline (.9%) followed by transcardial perfusion fixation using 
4% paraformaldehyde in acetate and then borate solution, as previously described (Croll et al., 





After 3-7 days in the buffered sucrose solution, brains were sectioned coronally at 50µm 
using a sliding microtome (American Optical Company, Buffalo, New York).  Sections were 
placed in a 24-well plate and stored in an ethylene glycol-based cryoprotectant solution (Watson 
et al., 1986) at -20 degrees Celsius until stained.  
Immunohistochemistry  
Glial fibrillary acid protein (GFAP): Sections were immunostained using a Vector stain Elite 
ABC kit (Vector Laboratories, Burlingame, CA, USA) and rabbit anti-glial fibrillary acid protein 
(GFAP rabbit polyclonal, 1:60,000, Dako, Carpinteria, CA, USA) commonly used to visualize 
astrocytes (for review see Scharfman et al., 2000). To control for non-specific binding of 
antibodies, sections of each animal were also stained with the same procedure with the exclusion 
of the primary antibody. These sections were examined and showed no specific staining pattern. 
GFAP immunostaining was conducted as follows: Tissue was rinsed several times for 15 minute 
intervals in 50mM of KPBS (90% D2H2O, 8% dibasic potassium phosphate, 2% monobasic 
potassium phosphate and sodium chloride). Next a blocking step was conducted where tissue 
was incubated for 20 minutes in KPBS containing 1% bovine serum albumin (BSA), .4% triton-x 
and 4% goat serum. Next the tissue was incubated in the primary antibody solution dilution of 
1:60,000 which contained KPBS, 1% BSA, .4% triton-x, 1% goat serum and rabbit anti-GFAP 
dilution of 1:1,500 overnight at 4⁰C. The next day, incubation continued in the primary antibody 
at room temperature for an additional 2 hours. Tissue was rinsed 10X for 10 minute intervals in 
KPBS containing with .25% BSA and .02% triton-x. Another incubation period followed in the 
secondary antibody for 60 minutes at room temperature, solution contained KPBS, 1% 
BSA, .02% triton-x and secondary antibody (goat-anti-rabbit, 33.33µl in 50 ml). Tissue was 
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rinsed again 4X for 15 minutes intervals in KPBS with .25% BSA. Tissue was incubated in an 
avidin: biotin: peroxidase complex (Vector Elite kit) for 1 hour with KPBS, 1% BSA and a 50/50 
mixture of reagents A & B. Tissue was rinsed again in plain KPBS 2X for 10 minute intervals, 
then again in Acetate-imidizole buffer solution (D2H2O, 1M sodium acetate and .2M imidazole) 
2X for 10 minute intervals. Tissue was developed in Chromagen solution for 2-10 minutes was 
deactivated using bleach. Chromagen solution contained D2H2O, 1M sodium acetate, .2M 
imidazole, Nickel II sulfate and DAB stock solution (10 mg/ml). Final rinses were done in 
acetate-imidazole buffer 2X for 10 minute intervals and then in buffered saline 2X for 10 
minutes and then left in buffered saline until mounted and coverslipped. Stained sections were 
viewed with an Olympus BX-51 microscope with a microfire camera by Optotronics. Astrocytes 
were traced using a 60X/1.42 oil lens and Neurolucida software (MicroBrightfield, Inc.). 
Glutamate Transporter 1 (GLT-1) 
One series of sections from each animal were immunostained for astrocyte glutamate 
transporter expression using the polyclonal antibody AB1783 antibody against GLT-1 
(Millipore, Billerica, MA, USA) using guinea pig anti-GLT1 as the primary antibody and a 
dilution of 1:350 with a goat-anti-guinea pig as the secondary antibody.  All tissues were 
exposed using a nickel sulfate-intensified diaminobenzidine (DAB) chromagen reaction.     
All procedural steps for immunohistochemistry were the same with the exception of the 
primary and secondary antibodies. In order to measure GLT-1 expression, hippocampal staining 
density was quantified by optical density (arbitrary units) via binary monochrome micrographs in 
Image J (Image processing and analysis in Java). The amount of illumination was kept constant 
during photomicroscopy by activating the photoillumination lock function on the microscope. A 
section that had coordinates between -2.8 and -4.3 posterior to bregma (Paxinos & Watson, 
1982) were used and photos of the hippocampus were taken from each section at the same 
38 
 
magnification (10X) which allowed for both the DG and CA1 regions to be visualized. Those 
photos were then turned into binary density photos and the area of immunoreactivity was 
calculated. Image J software microscope set-up contains a Microfire camera with a Nikon base 
and lens Eclipse E400 with a Plan 10X/0.25 lens. Process performed entailed subtracting the 
background, enhancing the contrast, making the picture binary and then quantifying using area 
measurement.  
Behavioral Tests 
Morris Water Maze: 
 The water maze apparatus consisted of a 5 foot diameter water maze filled with water 
made opaque by non-toxic paint.  One quadrant of the water maze contained a goal platform 
sunk approximately 3 cm beneath the surface.  Animals were placed at pseudorandom locations 
within the water maze and allowed to swim for 2 minutes or until they found the hidden goal 
platform on each trial.   Animals received three consecutive trials for each of the 4 days of 
testing, with an inter-trial interval of one minute. Latency to escape to the platform on trial days 
was recorded for each trial, and the median latency for each trial block was analyzed.  After the 
last trial on the fourth day the hidden goal platform was removed and an analysis of how much 
time was spent in the goal quadrant was measured indicating retention of the goal platform 
location. For this trial, animals were placed back into the maze at least one hour after their 
acquisition trials and were allowed to search for the platform for 30 seconds.  
Light/Dark Exploration Task: 
 The light-dark exploration task used a box that was divided into two sides, one white and 
uncovered and the other black and covered. Animals were placed into the light side and allowed 
to explore the box for 5 minutes. The proportion of time in the dark side was used as a measure 
of the animal’s level of anxiety. A high proportion of time spent in the dark, covered side 
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suggested preservation of anxiety.  
Open Field Locomotion Task: 
 To control for general locomotion and exploratory drive, a potential confound in our 
tasks, animals were placed in the middle of an open field and allowed to explore for 6 minutes. 
The open field was 3 feet x 3 feet square and was divided into 9 equally sized grids. The number 
of grids crossed during the trial was used as a measure of the animal’s locomotor activity. 
Quantification of Astrocytes 
 GFAP-stained astrocytes from two regions of interest (the dentate gyrus [DG] and CA1) 
in the hippocampus were quantified for all animals. Throughout the process of reconstruction 
and quantification the researcher was blinded to the animal number and the treatment group. All 
slides were coded by other members of the team or laboratory. After all quantifications were 
finished the animal number and group assignments were provided. 18 astrocytes were 
reconstructed, using neurolucida software for each animal. More particularly, ten astrocytes were 
reconstructed in the dentate gyrus region of the hippocampus beginning in the hilus and moving 
outward toward CA2. In the CA1 region, eight astrocytes were reconstructed from each animal 
starting from the same point (above but relative to hilus)medially to laterally every whole 
astrocyte encountered was traced until the pre-determined amount was acquired. A section that 
had coordinates between Interaural 6.2mm Bregma -2.8 and Interaural 4.7mm Bregma -4.3 
(Paxinos & Watson, 1982) were used for astrocyte tracing. Initially the region of interest (CA1 
or dentate gyrus) was located and centered under 4X/0.10/-FN22 (Plan N Olympus lens), then 
immersion oil was placed and the lens was switched to 60X/ 1.42 an oil lens ∞/0.17/FN26.5 
(Plan APO N Olympus lens) where the astrocytes were selected, reconstructed and analyzed. The 
dentate gyrus was done first and 10 astrocytes total were reconstructed for each animal; whereas 
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8 were located and reconstructed in the CA1 region. Each VEGF treatment condition consisted 
of 8 animals with 3 in each non-seized group and 5 in each seized group.   Once all 18 astrocytes 
were reconstructed using Neurolucida software (Microbrightfield, Inc.) both Branched structure 
and Sholl analyses were performed and Neuroexplorer was used to provide a detailed description 
of each astrocyte with a focus on measures that would be reflective of size and complexity of 
process development. The mean (for normally distributed parameters) or the median (for non-
Gaussian parameters) was calculated for all sampled astrocytes per animal per region, the 
measured parameters included soma size, astrocyte surface volume, length of processes, number 
of nodes, number of intersections, diameter of processes, as well as roundness and tortuosity. 
Additionally, the diameter, volume, and number of intersections by order of process branching 
were analyzed to reveal information more pertinent to branching complexity, and these 
parameters were all measured by either Branched structure or Sholl analyses.  The following 
parameters were measured via a Branched Structure Analysis (BSA): cell soma area, length tree 
total, average diameter and volume tree total were considered a measure of cell size. Also in 
BSA: mean length, number of processes, node count, base order for diameter at order 1 and order 
2, volume at Orders 1-3 and terminal quantity were considered to measure complexity or process 
development. Furthermore, the aspect ratio was quantified for each group and compared and 
defined as a measure of roundness. . In addition, a Sholl analysis was performed to examine the 
number of intersections with each concentric circle 5 microns apart in radius as moving away 
from the soma center; order of primary versus secondary and tertiary processes (with primary 
processes defined as those emerging from the cell soma area) whereas the subsequent orders 
were secondary, tertiary, and quarternary, respectively; level of complexity, in which the 
processes emerged from the cell soma at several levels of 5 micron radius. 
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 Finally, the mean distance between adjacent astrocytes was measured in pseudorandomly 
selected microscope fields by measuring the distance from the center of each astrocyte to its 
nearest neighbor using a quick line measure in Image J software (NIH).  In addition to 
calculating the mean distance between astrocytes for each animal, the variability in the distances 
was measured using the standard deviation as a measure of regularity of astrocyte spacing in 
each animal.  That is, those animals with higher standard deviations would show less regular 
spacing of astrocytes (i.e. spacing favoring clustering) whereas those with lower standard 
deviations would show regular spacing of astrocyte. 
 
Figure 3. Shows a diagram of a reconstructed astrocyte from the CA1 region that highlights the 
areas that were measured. 
Statistical Analyses  
  For most measures, a 2 (VEGF vs. inactivated VEGF) X 2 (pilocarpine vs. vehicle) 
independent groups factorial ANOVA was performed to order to compare differences between 
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the groups as well as interactions between VEGF treatment and seizures. In the case of 
interastrocyte distance and shape student t tests were performed to measure any differences 
between VEGF treatment groups in seized animals given the difficulty in some animals in non-
seized groups which did not show as much immunoreactivity. For measures which contained a 
repeated measures variable such as trial in water maze acquisition and in branch order in the 
branch structure and Sholl analyses a mixed model factorial ANOVA was conducted to quantify 
any changes resulting from the  independent variable group conditions.  In each case, significant 
interactions were further probed with a Scheffe post hoc test for simple main effects.  All 






Morris Water Maze:  
Learning and memory were analyzed using a modified Morris Water Maze. Data were 
analyzed using a 2 (VEGF treatment) X 2 (seizure) x 4 (trial block) mixed model factorial 
ANOVA. Treatment groups consisted of VEGF treated animals vs. inactivated VEGF control 
animals as one independent variable and pilocarpine-induced status epilepticus vs. saline controls 
as a second independent variable and trial blocks with latency to escape as the repeated measures 
variable. Results revealed an overall significant difference in learning between treatment groups 
(F (1, 70) =4.717, p=.033). Post hoc analyses revealed VEGF-treated seized animals showed 
significant improvement when compared to inactivated VEGF seized controls using Tukey’s 
LSD. This preservation of behavior was only partial as VEGF treated animals took significantly 
longer to find the platform when compared to non-seized animals. Additionally, swim speed was 
estimated using mean quadrant crossing time to ensure that increased latencies to escape did not 
reflect decreased swim speed.  Swim speed analysis revealed no significant difference between 
non-seized controls and VEGF seized animals (mean difference=.048, SEM=.31, p=.121) 







Figure 4.  A two-way mixed model factorial ANOVA revealed that VEGF-treated animals 
demonstrated partial preservation of learning and memory in the Morris Water Maze when 
compared to animals treated with inactivated VEGF. VEGF treated animals showed decreased 
latency to escape when compared to animals treated with inactivated VEGF. However, VEGF 




















































Light/Dark Exploration Task: 
 The number of transitions and time spent in the dark compartment were analyzed using a 
2 (VEGF treatment) x 2 (seizures) independent groups Factorial ANOVA with post-hoc 
comparisons as appropriate. Results showed a significant effect of pilocarpine (F(1,70)=7.829, 
p=.007) such that pilocarpine-treated animals spent significantly less time in the dark covered 
side of the apparatus, suggesting they were less anxious than animals who did not receive 
pilocarpine-induced SE. VEGF treatment had no significant effect on behavior in either seizure 
group (F(1,70)=.008, p=.928).  
 
Figure 5.  A One-way ANOVA resulted in a significant homogeneity test and therefore the 
corrected model of between-subjects effects was used and pairwise comparisons were done using 
a Tukey’s LSD to determine which treatment groups were significantly different. Results from a 
one-way ANOVA revealed an overall significant difference in the amount of time spent in the 





































decrease in normal anxiety behavior in animals receiving pilocarpine and inactivated VEGF 
treatment when compared to animals receiving pilocarpine and VEGF protein. 
Grid Locomotor Task: 
 Grid crossings on the open field were analyzed using a 2 (VEGF treatment) x 2 (seizures) 
independent groups Factorial ANOVA with post-hoc comparisons as appropriate. Results 
revealed no significant differences among experimental groups (F (3, 70) =2.080, p=.111) in 
relation to the amount of locomotor activity.  
 
 
Figure 6. A two-way Factorial ANOVA revealed no significant differences among experimental 




Figure 7. Hippocampus at lower magnification (4X/0.10) showing GFAP expression 
differences in animals that reached status epilepticus or did not seize after either VEGF protein 
or Inactivated VEGF control. 
 
Figure 8. Hippocampus at higher magnification (60X) showing GFAP expression differences in 
All 10 Dentate Gyrus 
astrocytes for each 
animal were 
pseudorandomly chosen   
All 8 CA1 astrocytes for 
each animal were 




animals that reached status epilepticus or did not seize after either VEGF protein or Inactivated 
VEGF control. 
Astrocyte Morphology 
Interastrocyte distance   
 VEGF significantly increased inter-astrocyte distance in both regions measured 
regardless of treatment (see Figures 9 &10). The line measure function from Image J was used to 
measure from the center of one astrocyte soma to the center of the nearest neighboring astrocyte 
soma as a reflection of inter-astrocyte distance and may reveal the changes observed such that 
astrocytes appeared more clustered. VEGF treatment resulted in a significant increase in inter-
astrocyte distance when measured from soma to soma between neighboring astrocytes, indicating 
that VEGF seemed to preserve the non-overlapping domain of astrocytes in the CA1 region 
(t(5)=-57.02, p=.001) in seized groups. However, no significant effect was found in the DG 
region (t (5) =-21.37, p=.081). Due to the complexity of cells, and their circuitry, in this region it 
is possible that a larger sample size may have been needed in order to detect any patterns of 
change based on VEGF.  








































Interastrocyte Distances of Pilocarpine-seized 





Figure 9. An independent groups Student’s t test shows mean distance between neighboring 
astrocytes measured one month after status epilepticus is significantly higher in animals treated 
with VEGF during status when compared to treatment with inactivated VEGF in the CA1 region 
of the hippocampus. As there was less GFAP expression in saline groups it was very difficult to 
find neighboring astrocytes in specific fields.  
 
 
Figure 10. No significant difference was found between VEGF and inactivated VEGF treated 
animals in the dentate gyrus. Cells in this region are highly variable and may make it difficult to 











































Interastrocyte Distance of Pilocarpine-seized 
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Figure 11. Shows the average astrocyte of the 8 astrocytes traced in CA1 region for each 
experimental condition. 
CA1 Region 
Size: VEGF treatment during SE significantly prevented post-SE increases in astrocyte cell body 
area (effect of VEGF: F(1,12)= 7.438, p=.018; effect of Pilocarpine: F(1,12)=11.912, p=.005; 
interaction: F(1,12)=7.940, p=.016,  see figure 13) and volume (effect of VEGF: 
F(1,12)=16.708,p=.002; effect of pilocarpine: F(1,12)=35.065, p=.001; Interaction 
F(1,12)=13.356,p=.003, see figure 14). A significant interaction effect of VEGF by pilocarpine 





the increases in length induced by status epilepticus (see figure 15).  Pilocarpine treatment 
significantly increased average astrocyte process diameter (F(1,12)=4.920, p=.047, see figure 16) 
but VEGF did not change this effect.  In addition, there was no interaction between the VEGF 
and pilocarpine treatments for average diameter F(1,12)=.189, p=.671. These findings suggest 
that although there were significant differences in size as a result of pilocarpine and/or VEGF 
treatment but differences in shape did not reach statistical significance. Additionally, aspect ratio 
was quantified and there were no statistically significant differences for the CA1 region as an 
effect of pilocarpine (F(1,12)=2.70, .126) or as an effect of VEGF treatment 
(F(1,12)=2.54, .137). However there was a trend in CA1 for the interaction of pilocarpine and 
VEGF treatment (F(1,12)=4.57, .054) suggesting that astrocytes in the pilocarpine group 
receiving VEGF treatment were more oblong than any other group.  Furthermore, aspect ratio 
showed no significant effect of pilocarpine (F(1,12=.243, .631), VEGF treatment 
(F(1,12)=.204, .660) or interaction between pilocarpine and VEGF treatment 






VEGF/Pilo SEM VEGF/Saline SEM VEGF/Pilo SEM 
Soma 
Area 11.130 2.400 53.438 11.788 11.844 2.037 16.965 2.069 
Total 
Length 25.906 5.677 37.797 2.917 27.469 2.456 23.154 0.598 
Average 
Diameter 0.316 0.001 0.928 0.328 0.259 0.030 0.670 0.193 
Total 
Volume 13.917 1.659 85.620 9.448 10.675 2.843 27.649 9.656 
 
Table 3. Shows all measures of size for the CA1 region of the hippocampus that includes soma 

















Figure 12. Shows the average astrocyte of the 10 astrocytes traced in dentate gyrus region for 
each experimental condition. 
 DG region Size:  VEGF treatment during SE significantly prevented post-SE increases in 
astrocyte cell body (effect of VEGF F(1,12)=11.414, p=.05), Pilocarpine (F(1,12)=15.952, 
p=.002) and an Interaction effect of VEGF by pilocarpine (F(1,12)=8.488, p=.013, see figure 
13). A similar effect of VEGF was observed for average diameter of processes (VEGF 
F(1,12)=13,186, p=.003), Pilocarpine (F(1,12)=20.713, p=.001) and Interaction of VEGF by 
pilocarpine (F(1,12)=8.458, p=.013, see figure 16). VEGF produced a similar effect on astrocyte 
volume (VEGF F(1,12)=7.675, p=.017), Pilocarpine (F(1,12)=5.415, p=.038), except that the 
interaction effect of VEGF by pilocarpine did not achieve significance (see figure 14). In 











VEGF/Pilo SEM VEGF/Saline SEM VEGF/Pilo SEM 
Soma 
Area 18.223 7.978 53.820 5.420 15.657 3.295 21.426 2.610 
Length 
Total 24.546 1.239 29.683 2.864 26.364 2.329 25.262 2.868 
Average 
Diameter 0.389 0.099 1.180 0.130 0.313 0.023 0.490 0.130 
Volume 
Total 23.896 12.679 70.629 14.725 14.625 2.345 19.024 2.106 
 
Table 4. Shows all measures of size for the dentate gyrus region of the hippocampus that 
includes soma area, total process length, average process diameter and average total volume. 
 
 
Figure 13.  Pilocarpine-induced SE resulted in significant increases in soma area of the 
astrocytes in both the CA1 and DG regions of the hippocampus. VEGF treatment significantly 
reduced the increase in soma area of astrocytes in both CA1 and DG regions of the hippocampus 
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Symbols: Pilocarpine effect * p<.05, ** p<.01, VEGF effect # p<.05, ## p<.01, significant 
(p<.05) interaction effects between variables are indicated by an X. 
 
Figure 14. Pilocarpine-induced SE resulted in a significant increase in the total volume of the 
astrocytes in both the CA1 and DG regions of the hippocampus. VEGF treatment significantly 
attenuated the pilocarpine-induced changes in volume in both CA1 and DG regions. Symbols: 
Pilocarpine effect * p<.05, ** p<.01, VEGF effect # p<.05, ## p<.01, significant (p<.05) 
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Figure 15. A significant interaction was found between VEGF and pilocarpine treatments 
In CA1 region of the hippocampus such that pilocarpine increased length and VEGF treatment 
prevented this effect in seized animals. Significant (p<.05) interaction effects between variables 
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Figure 16. Pilocarpine treatment significantly increased the average process diameter in both the 
CA1 and DG regions of the hippocampus, however VEGF treatment did not significantly 
attenuate this change in the CA1 region. Symbols: Pilocarpine effect * p<.05, ** p<.01, VEGF 
effect # p<.05, ## p<.01, significant (p<.05) interaction effects between variables are indicated 
by an X.  
CA1 Region 
Complexity: Measures reflecting astrocyte branch complexity such as node count revealed 
significant effects of both VEGF (F(1,12)=7.117, p=.020) and pilocarpine (F(1,12)=6.833, 
p=.023) such that pilocarpine leading to status significantly increased complexity across 
measures, whereas VEGF decreased complexity (see figure 19).  In addition, there was a 
significant interaction between VEGF and pilocarpine treatments such that VEGF consistently 
attenuated the increased complexity induced by pilocarpine-induced status (F(1,12)=5.347, 
p=.039).  Other measures of complexity showed a similar pattern of effects as that described for 
node count as follow: volume at Order 1 revealed a significant effect of VEGF (F(1,12)=14.592, 
p=.002) and pilocarpine (F(1,12)=37.343, p=.001) and an interaction effect between the two 
(F(1,12)=10.310, p=.007); volume at  Order 2 a significant effect of VEGF (F(1,12)=17.906, 
p=.001) and pilocarpine (F(1,12)=29.921, p=.001) and an interaction between the two 
(F(1,12)=13.814, p=.003); volume at Order 3 a significant effect of VEGF (F(1,12)=8.514, 
p=.013) and pilocarpine (F(1,12)=25.756, p=.001) and an interaction between the two 
(F(1,12)=8.972, p=.011) (see figures 22 & 23).  
 The total number of processes revealed a significant effect of VEGF such that VEGF 
decreased the total number of processes regardless of seizure status (F(1,12)=6.833, p=.023) (see 
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figure 18). In contrast, VEGF did not significantly affect mean length (see figure 17), however 
the interaction between VEGF and pilocarpine showed a statistical trend consistent with those 
observed for other measures of complexity (F(1,12)=4.185, p=.063). Additionally, no effect of 
VEGF was found at base diameter at orders 1 or 2 (see figures 20 & 21), whereas Pilocarpine 
significantly increased mean length (F(1,12)-6.902, p=.022), base diameter at order 1 
(F(1,12)=9.114, p=.011), and base diameter at order 2 (F(1,12)=8.454, p=.013). No significant 
effect was found for either VEGF or pilocarpine when measuring Terminal quantity.  Together 
these results suggest that VEGF is attenuating many, but not all, parameters that are normally 
altered following seizures.  
 
Table 5. Shows all measures reflecting complexity in CA1 region of the hippocampus including 
mean length of processes, node count, number of processes, process volume by branching order 
and process diameter by branching order. 
DG Complexity: Measures reflecting branch complexity in the dentate gyrus showed 






VEGF/Pilo SEM VEGF/Sal SEM VEGF/Pilo SEM 
Mean 
Length 4.557 1.232 13.167 0.735 5.269 2.336 6.340 1.987 
Node 
Count 3.500 0.433 7.162 0.674 3.236 0.617 3.460 1.083 
Number of 
Processes 6.042 0.397 5.625 0.402 5.721 0.575 7.665 0.180 
Vol Order 
1 8.190 0.418 32.940 3.061 6.573 1.524 14.273 3.704 
Vol Order 
2 4.685 1.660 36.727 4.445 2.889 1.000 9.005 4.390 
Vol Order 
3 0.916 0.504 11.686 1.805 1.019 0.564 3.795 1.805 
Diameter 
Ord 1 0.212 0.014 0.297 0.027 0.203 0.027 0.289 0.030 
Diameter 
Ord 2 0.466 0.062 1.482 0.342 0.388 0.055 0.761 0.158 
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significant effect of VEGF (F(1,12)=11.890, p=.005) and pilocarpine (F(1,12)=11.327, p=.006) 
as well as an interaction effect of VEGF by pilocarpine (F(1,12)=8.492, p=.013); volume at  
Order 2 a significant effect of VEGF (F(1,12)=5.982, p=.031); volume at Order 3 a significant 
effect of VEGF (F(1,12)=8.550, p=.013); node count a significant effect of VEGF 
(F(1,12)=5.254, p=.041), but no significant effect of Pilocarpine (F(1,12)=.023, p=.882) or 
interaction effect (F(1,12)=.118, p=.737). A significant effect of Pilocarpine was found for mean 
length (F(1,12)-13.305, p=.003), with no significant effect of VEGF alone and a statistical trend 
for the interaction between the two (F(1,12)=4.30, p=.060). For base diameter at order 1 there 
was a significant effect of Pilocarpine (F(1,12)=13.090, p=.004) but no effect of VEGF and at 
base diameter at order 2 a significant  effect of VEGF (F(1,12)=8.611, p=.012) and Pilocarpine 
(F(1,12)=8.602, p=.013) but no significant interaction effect.  No significant effect was found for 







VEGF/Pilo SEM VEGF/Sal SEM VEGF/Pilo SEM 
Mean 
Length 3.668 0.359 13.548 0.735 4.456 1.938 7.174 2.959 
Node 
Count 5.408 1.501 5.240 0.507 3.100 0.785 3.533 0.467 
Number of 
Processes 7.058 0.412 6.733 0.384 6.180 0.403 7.580 0.676 
Volume 
Order 1 11.809 4.476 36.120 4.909 9.741 1.821 11.489 0.992 
Volume 
Order 2 8.477 5.222 24.212 6.329 3.817 0.925 5.970 0.876 
Volume 
Order 3 2.424 1.871 6.364 1.215 0.933 0.523 1.279 0.383 
Diameter 
Order 1 0.188 0.031 0.351 0.400 0.202 0.013 0.259 0.004 
Diameter 
Order 2 0.602 0.202 1.033 0.107 0.333 0.083 0.602 0.067 
 
Table 6. Shows all measures reflecting complexity in dentate gyrus region of the hippocampus 
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including mean length of processes, node count, number of processes, process volume by 
branching order and process diameter by branching order. 
 
 
Figure 17. Pilocarpine treatment significantly increased the length of primary, secondary, and 
tertiary order branches. VEGF significantly reduced the length at these orders of process 
branching in the CA1 region. Symbols: Pilocarpine effect * p<.05, ** p<.01, VEGF effect # 


















































































Figure 18. VEGF significantly attenuated the number of processes in the CA1 region of 
The hippocampus. No significant results were found in the DG region of the hippocampus. 
 
Figure 19. Pilocarpine treatment significantly increased the mean number of nodes in 
the CA1 region of the hippocampus and VEGF treatment significantly attenuated this change. 
Additionally, VEGF significantly decreased the number of nodes in the DG region of the  
hippocampus in seized animals. Symbols: Pilocarpine effect * p<.05, ** p<.01, VEGF effect # 
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Figure 20. A statistical trend was found at order 2 in CA1 region of the hippocampus, as 
indicated by a ^, between VEGF and inactivated VEGF animals that seized, such that VEGF 
decreased mean diameter. significant (p<.05) interaction effects between variables are indicated 
by an X.  
 
Figure 21. A significant effect of pilocarpine was found in the diameter of order 1 branches in 
the DG region of the hippocampus but VEGF had no significant effect on this change. However, 
at order 2 there was a significant effect of pilocarpine such that there was an increase in diameter 
and VEGF treatment significantly decreased the diameter in seized animals. Symbols: 
Pilocarpine effect * p<.05, ** p<.01, VEGF effect # p<.05, ## p<.01, significant (p<.05) 
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Figure 22. There was a significant effect of pilocarpine on increasing mean branch volume at all 
three orders. A significant effect of VEGF treatment was also found at all three orders of volume 
showing that VEGF treatment significantly decreased volume in seized animals.  An interaction 
between the two variables was found at all three orders. Symbols: Pilocarpine effect * p<.05, ** 
p<.01, VEGF effect # p<.05, ## p<.01, significant (p<.05) interaction effects between variables 
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Figure 23. Pilocarpine significantly increases branch volume at order 1 and produced a statistical 
trend toward a difference at order 2 without affecting order 3 volumes. A significant effect of 
VEGF treatment on volume was found at all three orders such that VEGF treatment significantly 
decreased volume in seized animals. An interaction between the two variables was found at order 
1. Symbols: Pilocarpine effect * p<.05, ** p<.01, VEGF effect # p<.05, ## p<.01, significant 
(p<.05) interaction effects between variables are indicated by an X. and a statistical trend as ^. 
Sholl Analysis  
   A Sholl analysis was conducted to determine branch characteristics at different orders 
or distances from the astrocyte cell bodies.  This analysis revealed a significant increase in the 
number of intersections in animals receiving pilocarpine-induced SE when compared to non-
seized animals (Λ = .041, F(1/12)=14.749, p=.004). Seized animals receiving inactivated VEGF 
demonstrated significantly more intersections when compared to those in the VEGF or the non-
seized groups. A significant effect of VEGF treatment revealed (Λ=.090, F(1  ,12  )= 6.289 , 
p=.029),that less branching occurred at an earlier order from the soma in animals treated with 
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interaction effect between Pilocarpine and VEGF was also found, reflecting that VEGF 
prevented or attenuated the increases observed with pilocarpine (Λ=.085, F(1,12)=6.755, 
p=.025). 
 
Figure 24.  A Sholl analysis revealed a within subjects effect of number of intersections at 
various radius locations as moving from the soma outward in CA1 region of significant 
interaction with pilocarpine (Λ = .041, F(1/12)=14.749, p=.004), significant interaction with 
VEGF (λ=.090, F(1,12 )= 6.289, p=.029) and a triple interaction with the two independent 
variables (Λ=.085,F(1,12)=6.755, p=.025); between subjects effects revealed no significant 
effect of pilocarpine (F(1,12)=1.231, p=.289), a significant effect of VEGF (F(1,12)=4.465, 
p=.053) and no interaction between the two (F(1.12)=3.895, p=.072). For DG region within 
subjects effects showed no significant interaction with pilocarpine (Λ=.143 F(1.12)=3.757, 
p=.081) and a significant interaction with VEGF (Λ=.016 F(1,12)=39.016, p=.016) and no triple 
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effects of pilocarpine (F(1,12)=.641, p=.439), VEGF (F(1,12)=3.445, p=.088) and no interaction 
between the two (F(1,12)=.471, p=.506).   Symbols: Pilocarpine effect * p<.05, ** p<.01, VEGF 
effect # p<.05, ## p<.01, significant (p<.05) interaction effects between variables are indicated 
by an X. 
 
 
Figures 25 a,b,c&d.  The results of a Sholl Analysis are shown with each treatment group 
represented in a separate graph to better reveal process patterning. Inactivated VEGF treated 
animals that seized are represented by the red line and VEGF treated animals that seized are 
represented by the blue line in the graphs below. Inactivated controls are represented by the 
purple line and VEGF treated controls are represented by the green line. This is a measure of the 
process length at each order. Primary processes were defined as those emerging from the cell 
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soma area whereas subsequent orders were secondary, tertiary, quarternary respectively (Orders 
2-4). Showing VEGF attenuates seizure-induced pathological branching complexity; whereas 
inactivated VEGF controls appeared to demonstrate an increase in branching complexity in the 
CA1 region of the rat hippocampus. An ANOVA test was performed using increments of 5 
microns in each Radius.   
 
Glutamate Transporter (GLT-1) Expression: 
 GLT-1 expression was measured by optical density via binary monochrome micrographs 
(40X) in both CA1 and the dentate gyrus regions of the hippocampus. A between subjects 2 
(VEGF treatment) X 2 (seizure) ANOVA revealed no significant effects of pilocarpine or VEGF 
treatment on their own, but the interaction between the two variables showed a statistical trend 
(F(1,17)=4.289, p=.054, see figure 22) for . However, in the dentate gyrus region pilocarpine 
showed a statistical trend toward decreasing Glt-1 expression (F(1,17)=3.591, p=.075, see figure 
22). There was no significant effect of VEGF treatment. It is possible that due to the nature of the 
variability of the cells and structure, as well as the complex connectivity within the hilus, more 




Figure 26. Optical density measurements for GLT-1 immunoreactivity showed no significant 
effect of any of the treatments on Glt-1 expression, although there was a statistical trend toward 
an effect of pilocarpine decreasing Glt-1 expression in the dentate gyrus.  
Correlations Between Astrocyte Parameters and Behavior: 
 Correlation analyses revealed a significant relationship between measures of size and 
complexity of the astrocytes and the performance of the animals in the water maze for both 
measures of acquisition and retention (see Tables 7-14 for statistics and details). Results suggest 
that the pilocarpine-induced changes in measures of size and complexity, which were attenuated 
by VEGF, significantly correlated with the partial behavioral preservation observed in these 
animals. Particularly, soma area, diameter and volume totals as well as measures of complexity 
such as number of processes, node count, volume by order and in some cases diameter by order 






































Region      
Latency 
Block 4 
SA Diameter   Length   Volume 
Latency 
Block 4 
1 0.849** 0.611** 0.402 0.922** 
Soma Area 
CA1 




0.611** 0.548* 1 0.428 0.724** 
Length total 
CA1 
0.402 0.455 0.428 1 0.639** 
Volume 
total CA1 
0.922** 0.895** 0.724** 0.639** 1 
 
Table 7. The correlation table shows the correlation coefficients between astrocyte size 
measurements in the CA1 region of the hippocampus as predictors of learning acquisition in 
MWM.  Results show that size measures in CA1 were significantly positively correlated to 
learning acquisition in MWM such that as the size of astrocyte increased so did the animal’s time 
to find the platform. *p<.05, **p<.01, ***p<.001 
Acquisition             
Size DG  
Lat bl 4 SA Diameter Length Volume 
Latency 
Block 4 
1.000 0.690** 0.778** .125 0.632** 
Soma Area 
DG 




0.778** 0.929** 1.000 .079 0.890** 
Length 
Total DG 
.125 .047 .079 1.000 .153 
Volume 
Total DG 
0.632** 0.918** 0.890** .153 1.000 
 
Table 8. Correlation table shows the size measurements in DG region of the hippocampus as 
predictors of learning acquisition in MWM. Results show that size measure in DG were 
69 
 
moderately to strongly significantly positively correlated to learning acquisition in MWM such 
that as the size of astrocyte increased so did the animal’s time to find the platform. *p<.05, 
**p<.01, ***p<.001. 
 
Table 9. Correlation table shows measures of complexity in CA1 region of the hippocampus as 
predictors of behavioral learning acquisition in MWM.  The following measures of complexity 
were significantly related to the time to find the platform in acquisition trials such that as 
measures of complexity were decreasing the time to find the platform decreased. VEGF-treated 
animals demonstrated improved learning and significantly shorter times to find the platform over 
the trial days when compared to animals that seized but received inactivated VEGF. This was 
only partial preservation of learning behavior as VEGF treated animals also took significantly 





LatBL4 ML PC NC D1 D2 V1 V2 V3 
LatBL4 1 .652** .458* .698** .761** .808** .913** .915** .865** 
Mean 
Length 
.652** 1 .543* .820** 0.402 .709** .810** .841** .860** 
Process Ct .458* .543* 1 .591** 0.272 .577** .694** .641** .597** 
Node Ct .698** .820** .591** 1 .552* .830** .844** .851** .909** 
DiamOrd1 .761** 0.402 0.272 .52* 1 .599** .634** .624** .673** 
DiamOrd2 .808** .709** .577** .830** .599** 1 .867** .894** .879** 
VolOrd1 .913** .810** .694** .844** .634** .867** 1 .983** .925** 
VolOrd2 .915** .841** .641** .851** .624** .894** .983** 1 .929** 





Table 10.  Correlation table shows measures of complexity in DG region of the hippocampus as 
predictors of behavioral learning acquisition in MWM.  The following measures of complexity 
were significantly related to the time to find the platform in acquisition trials such that as 
measures of complexity were decreasing the time to find the platform improved. VEGF treated 
animals demonstrated improved learning and significantly shorter times to find the platform over 
the trial days when compared to animals that seized but received inactivated VEGF. However, 
this was only partial preservation of learning behavior as VEGF treated animals were also took 







LatBL4 ML PC NC D1 D2 V1 V2 V3 
LatBL4 1 .587** 0.08 0.219 .771** .595** .692** .508* .629* 
Mean Length .587** 1 0.242 0.094 .772** .699** .804** .700** .562** 
Process CT 0.08 0.242 1 0.355 0.132 0.362 0.395 .583** 0.437 
Node Ct 0.219 0.094 0.355 1 0.011 .630** 0.379 .671** .704** 
DiamOrd1 .771** .792** 0.132 0.011 1 .507* .675** .485* .514* 
DiamOrd2 .595** .699** 0.362 .630** .507* 1 .825** .892** .867** 
VolOrd1 .692** .804** 0.395 0.379 .675** .825** 1 .902** .857** 
VolOrd2 .508* .70** .583** .671** .485* .892** .902** 1 0.922 





GQ SA D L V 
Goal Quad 1 .-0.456* -0.292 -0.14 .-0.608** 
Soma Area .-0.465 * 1 0.548* 0.455* 0.895** 
Diameter -0.292 0.548* 1 0.428 0.724** 
Length -0.14 0.455* 0.428 1 0.639** 
Volume .-0.608** 0.895** 0.724** 0.639** 1 
 
Table 11. Correlation table showing astrocyte size measurements in the CA1 region of the 
hippocampus as predictors of memory in the MWM.  These measures were negatively correlated 
such that as size measures decreased the time spent in the goal quadrant increased suggesting the 
animals remembered the location of the platform better as astrocytes decreased in size. *p<.05, 
**p<.01, ***p<.001. 
 
Retention Size DG  Goal Quadrant SA D L V 
Goal Quadrant 1 -0.259 -0.351 -0.052 -0.249 
Soma Area -0.259 1 .929** 0.047 .918** 
Diameter -0.351 .929** 1 0.079 .890** 
Length -0.052 0.047 0.079 1 0.153 
Volume -0.249 .918** .890** 0.153 1 
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Table 12. Correlation table showing the size measurements in the DG region of the hippocampus 
as predictors of memory in MWM. Measures were negatively correlated such that as size 
measures decreased the time in the goal quadrant increased suggesting the animals remembered 





TG ML PC NC D1 D2 V1 V2 V3 







-0.228 1 .543* .820** 0.402 .709** .810** .841** .860** 
Process Ct -0.337 .543* 1 .591** 0.272 .577* .694** .641** .597** 
Node Ct .-.486* .820** .591** 1 .552* .830** .844** .851** .909** 
DiamOrd1   
-
.673** 
0.402 0.272 .552* 1 .599** .634** .624** .673** 
DiamOrd2   
-.490* 
.709** .577* .830** .599** 1 .867** .894** .879** 
VolOrd1   
-
.647** 
.810** .694** .844** .634** .867** 1 .983** .925** 
VolOrd2   
-.575* 
.841** .641** .851** .624** .894** .983** 1 .929** 
VolOrd3 -.568** .860** .579** .909** .673** .879** .925** .929** 1 
 
Table 13.  Correlation table showing the complexity measurements in the CA1 region of the 
hippocampus as predictors of memory in MWM. As size measures were decreased the time spent 








TG ML PC NC D1 D2 V1 V2 V3 
Time Goal 
Quad 
1.000 -.180 -.187 -.223 .-.448* -.254 -.253 -.190 -.339 
Mean 
Length 
-.180 1.000 .242 .094 .792** .699** .802** .700** .562* 
Process Ct 
DG 
-.187 .242 1 .355 .132 .362 .395 .583* .437 
 Node CT 
DG 
-.223 .094 .355 1 .011 .630** .379 .671** .704** 
DiamOrd1 
DG 
.-.448* .792** .132 .011 1 .507* .675** .485* .514* 
DiamOrd2 
DG 
-.254 .699** .362 .630** .507* 1 .825** .892** .867** 
VolOrd1 
DG 
-.253 .804** .395 .379 .675** .825** 1 .902** .857** 
VolOrd2 
DG 
-.190 .700** .583* .671** .485* .892** .902** 1 .922** 
VolOrd3 
DG 
-.339 .562** .437 .704** .514* .867** .857** .922** 1 
 
Table 14.  Correlation table showing the complexity measurements in DG region of the 
hippocampus as predictors of memory in MWM. The measures of complexity were negatively 
correlated with the behavior such that as size measures were decreased the time spent in the goal 




Chapter 3: Discussion 
Previous work from our laboratory showed that 2-4 weeks following pilocarpine-induced 
seizures in animals that had received VEGF during status epilepticus had significantly improved 
behavioral status when compared to those receiving inactivated VEGF (Nicoletti et al., 2010).  
However, the VEGF-treated group showed no difference in neuronal loss in the hippocampus at 
this time point, suggesting that VEGF's ability to preserve behavioral performance was unrelated 
to direct neuroprotection (Nicoletti et al., 2008). The mechanisms underlying this transient 
protection are currently unknown and warrant further investigation. However, the fact that 
behavioral preservation occurred in the absence of continued neuronal preservation, suggests that 
VEGF induced other enduring changes in the hippocampus that led to functional preservation. 
VEGF treatment has a “quieting effect” on neurons, which appears to be independent of changes 
in intrinsic neuronal properties (McCloskey et al., 2005), suggesting a potential contributory role 
of circuit changes, or of other cells, in VEGF’s effects on hippocampal function.  
Studies have proposed that other cell types contribute both to circuit function and seizure 
activity in the hippocampus.  For instance, astrocytes have calcium oscillations have the ability 
to facilitate seizures and increases in astrocytic calcium are sufficient to cause local paroxysmal 
depolarization (Tian et al., 2005). Reports have been accumulating regarding the possibility of an 
astrocytic basis for epilepsy through Ca++-dependent glutamate release (Haydon, 2001; Ye et 
al., 2003; Tian et al., 2005). In addition, some data suggests that disturbed astroglial receptor 
function might contribute to pathological conditions and hyper-excitability in human epilepsy 
(Seiffert et al., 2004).  
 Given that astrocytes have been reported to have VEGF receptors and to be VEGF 
responsive, it is possible that administration of VEGF in our experiments altered astrocyte 
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morphology and function.  
Summary of Results 
The current study measured astrocyte morphological and patterning parameters one 
month after status epilepticus to understand whether changes in astrocytes treated with VEGF 
would correlate with the functional improvements observed with VEGF treatment. Behavioral 
results revealed a significant effect of seizures on Morris water maze (MWM) performance for 
both acquisition and retention, such that seized animals showed a marked impairment in 
performance as we have reported previously (Nicoletti et al., 2010).  Also in agreement with our 
previous results, VEGF significantly improved the MWM performance of pilocarpine-treated 
animals, suggesting that it contributes to functional preservation.  Seizures also significantly 
impaired anxiety-like behaviors in the light-dark task, and but this impairment was not 
significantly reversed by VEGF treatment in the current study as we have previously reported 
(Nicoletti et al., 2010).   
Unlike neuron counts (Nicoletti et al., 2010), astrocyte morphology was significantly 
different in VEGF-treated animals one month after status epilepticus.  Interastrocyte distances 
were measured as a way to reflect if VEGF may be attenuating the overlapping among processes 
frequently observed in astrocytes from seizure models and in human epilepsy. VEGF had a 
significant effect in increasing the amount of distance between neighboring astrocytes, 
suggesting that VEGF did prevent the loss of astrocytic domain organization observed in chronic 
epilepsy. VEGF also significantly reduced the process branching complexity and the length the 
processes reach at later orders. More particularly, VEGF reduced the number of branch orders 
and the extension from the soma outward. This finding could suggest that VEGF is preventing 
the processes from entering into the domains of other astrocytes, which may assist in preventing 
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the spread of depolarization and or the release of glutamate under conditions of excitotoxicity. It 
may also allow for more efficient information processing and therefore make behavioral 
recovery more likely due to proper communication between endothelium, astrocytes, microglia 
and therefore neurons. 
Correlation and regression analyses using astrocyte size measures and process branching 
complexity measures as predictors of both acquisition and retention in the water maze revealed a 
significant negative correlation between process complexity and a positive correlation between 
astrocyte size and cognitive parameters. These data suggest that larger, more branched astrocytes 
were more likely to be associated with poor cognitive performance.  Because treatment with 
VEGF during SE reduced astrocyte size and complexity, VEGF treatment was also associated 
statistically with improved cognitive performance.  It is important to note that VEGF in this 
study was no longer on board at the time of behavioral testing and that tissue was only taken 
after the behavioral tests were completed in all cohorts.  Therefore, it is not known if the changes 
that we observed in astrocyte parameters were in place for the entire month after SE. That is, we 
cannot say for certain whether VEGF itself led to these changes, whether withdrawal from 
VEGF led to the changes, or whether alterations in hippocampal function and structure caused by 
VEGF acutely led to lasting alterations in astrocyte and functional parameters. Additionally, we 
cannot be sure if the astrocyte differences observed in the VEGF-treated group caused the 
preservation of behavior or if other variables that were normalized in the system by VEGF also 
prevent SE-induced changes to astrocytes. Furthermore, there were differences observed between 
the CA1 and DG regions of the hippocampus with a higher variability found in the dentate gyrus 
region when compared to the CA1 region. It is possible that this increased variability may be 
explained by the differences in the cell variety and the differences in the complexity of the neural 
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circuitry in these two regions For example, studies report some cells in the dentate gyrus fire in 
multiple locations whereas other cells fire in a single location more similar to CA1 place cells 
(Jung & McNaughton, 1993; Leutgeb et al., 2007) and these different firing patterns may lead to 
more complex circuitry. Other possible explanations may involve the increased amount of 
genesis that occurs in the dentate gyrus and the age of the cells in this location. Therefore, it may 
be interesting to investigate the age of the astrocytes using markers such as glutathione transport 
or D-serine racemase which are only found in mature astrocytes but not mature NG2+ cells or 
young astrocytes (Parpura & Haydon, 2009). 
Astrocytes and Hippocampal Function 
 Astrocytes serve many roles that may be compromised following SE or chronic seizures 
and are crucial to proper CNS communication. For instance, tight astrocyte end feet junctions 
form the BBB and a link to neurons, balance of water via AQP4 channels, proton shuffling such 
as Na+/H+, clearance of glutamate and K+ from extracellular space, glutamate conversion to 
glutamine, secretions such as thrombospondin for synapse formation, gap junction networks that 
allow for transport of important substances like glucose for neuronal fuel, direct contact with 
neural progenitor cells and the “tripartite synapse” in which astrocytes play a direct and 
interactive role with neurons during synaptic activity and are critical for information processing 
by neuronal circuits (Sofroniew & Vinters, 2010).  
Here we report that significant changes in astrocyte morphology were observed in 
animals that had undergone pilocarpine-induced SE, and that VEGF attenuated changes that 
were reflective of size such as soma area, total volume and average diameter as well as process 
branching and branching complexity. Overall, VEGF appeared to reduce the size and complexity 
of the astrocytes and their processes and may therefore have resulted in a decrease in domain 
organizational changes, metabolic disturbances, distribution changes or receptor function, or 
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even alterations in astrocyte secretions or enzymes.  Many questions remain about all the effects 
VEGF could be having on the astrocytes that were not measured in this work. For instance, 
another study from our lab suggested that VEGF reduces the level of glucose transporter (Glut-1 
& 4) expression on brain vasculature adjacent to astrocytes (Scorpio et al., 2012). Furthermore, 
animals that had undergone pilocarpine-induced seizures showed an increased level of glucose 
transporter expression, perhaps in response to an increased metabolic load.  This increase in 
glucose transporters was accompanied by a decrease in glucose transport into the brain (Scorpio 
et al., 2012). Therefore VEGF may protect neurons, in part, by reducing their oxidative 
production and limiting glucose availability.  
Astrocytes change following SE and reports show loss of organizational domains, 
reactive gliosis, secretion changes, redistribution of AQP4, increased Na+ and Ca++ channels, 
decreased Kir4.1 channels, reduced GS and lactate dehydrogenase as well as increased immune 
molecules. Astrocytes showing these changes can be categorized into differing populations such 
as strong GFAP reactive and weak GFAP reactive cells, where the weaker cells resemble GluR 
astrocytes and are known as NG2+ cells. The functioning of these subtypes and or loss of one 
type may lead to favored hyper-excitability and may trigger seizure spread even in a fairly 
normal subiculum (Nobel, 2012). Work from the Nedergaard laboratory showed that reactive 
astrocytes were increased in many types of seizure models and produced excessive glutamate 
that could not be caused by neural firing as it was abolished. This group reported that reactive 
astrocytes trigger epilepsy as opposed to the other way around (Tian et al., 2005) and suggested 
there is a great need for treatments that do not slow down synaptic activity but rather control 
glutamate release or inhibits reactive astrocytes. Other work from this lab proposes that 
reorganization of astrocytes, along with dendritic sprouting and new synapse formation, may 
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form the structural basis for recurrent excitation in the epileptic brain (Oberheim et al., 2008). 
Finally, Tian and colleagues found robust gliosis may play a role due to imbalance of ionic 
homeostasis, changes in volume that lead to neuronal hyper-synchrony and or by controlling the 
synaptic strength between specific populations of neurons (Tian et al., 2005). The same group 
found that intracellular Ca++ waves could facilitate seizures and can propagate therefore 
resulting in long-range changes in excitation between neurons that were not synaptically 
connected.  
Together these findings propose an astrocytic basis for seizure generation and even for 
recurrent seizures that may lead to circuitry that favors hyper-excitability. The current work 
demonstrated changes in size and branching complexity in animals receiving pilocarpine-induced 
SE and showed a significant effect of VEGF on attenuating these changes.  Based on published 
studies about the properties of reactive astrocytes, it seems likely that the astrocyte changes we 
measured after SE in our experiments favored a reactive phenotype. As the measures of size and 
complexity were significantly correlated with preserved behavioral function in the water maze, 
this may suggest that the effect of VEGF was neuroprotective. This neuroprotection may have 
been related to both preservation of astrocytic domain organization and metabolic rescue; both of 
which could contribute to neuronal function.  
Reactive Astrogliosis 
Reactive astrocytes are reported to be important in the prevention of inflammation 
spreading immediately following insult or injury. Additionally, reports show preventing reactive 
astrocytes early on can prevent or slow recovery. For instance, Faulkner’s group showed that 
ablating reactive astrocytes at an early time point prevented motor recovery in a model of spinal 
cord injury (2004). Other studies have concluded that loss of astrocytes early on leads to 
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secondary degeneration of other cell types (Lui et al., 1999; Zhao et al., 2003) due to 
accumulation of extracellular glutamate causing excitotoxicity in neurons and oligodendrocytes 
(Bush et al., 1999).  
In spite of findings suggesting a beneficial contribution of reactive astrocytes 
immediately after injury, reactive gliosis long-term may be detrimental to repair and recovery 
following insult. Pekny and several colleagues (2004) have published data showing that reactive 
gliosis can be beneficial immediately following insult or injury; and yet can be harmful to the 
recovery of the system due to glial scarring and inhibited neurogenesis in adult animals. For 
instance this group showed that mice deficient in two intermediate filament proteins, GFAP and 
Vimentin, which are upregulated and thought of as hallmarks of reactive gliosis, exhibit 
attenuation of reactive gliosis post-trauma.  These same mice showed improved integration of 
neural grafts as well as improved post-trauma regeneration in an ischemic model (Wilhelmsson 
et al., 2004).  These mice showed initial synaptic loss, but there was a complete synaptic 
regeneration later on supporting the idea that reactive gliosis early on plays a beneficial role, 
while prolonged gliosis causes problems in regeneration at a later stage. Pekny and colleagues 
(2007) suggested that reactive astrocytes may be key targets for novel interventions.  
Astrocytes & Glutamate Cycling  
Astrocytic function is a key player in metabolism as neurons and astrocytes are coupled 
in metabolism and the site of interaction for this coupling is at the synapse. Perhaps the most 
important role for astrocytes at this site is the removal of K+ ions and glutamate, which 
accumulate in the microenvironment during synaptic activity. Astrocytes provide the neurons 
with glutamine and lactate needed for the rapid turnover of ionic gradients.  
Astrocytes provide a cellular connection to neurons as well as providing a balance of 
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excitation and inhibition. Astrocytes contribute to neurotransmission by regulating the 
concentration of ions and neurotransmitters in the synaptic cleft, therefore influencing control 
over synaptic efficacy (Barres, 2003). Gliotransmitters released by astrocytes may activate 
receptors in neurons to modulate excitatory and inhibitory synaptic transmission and because 
astrocytes can reach thousands of synapses simultaneously, this release may lead to 
synchronization of neuronal firing patterns. Astrocyte dysfunction could also cause an 
interruption or dysfunction in the glutamate-glutamine cycle, which is so crucial to the balance 
of excitation and inhibition.   
The first step in the astrocyte glutamate-glutamine cycle in astrocytic transport of 
glutamate is uptake.  This glutamate transport is crucial to proper neuronal functioning, and 
deletion of genes that encode for these transporters results in glutamate-mediated excitotoxicity 
(Rothstein et al., 1996). Astrocytes are responsible for up to 90% of glutamate uptake from the 
extracellular space (Behrens et al., 2002) and pharmacological inhibition of the GLT-1 astrocyte 
glutamate transporter reduces the threshold for epileptiform activity.  GLT-1 alterations are 
reported in many neurological disorders such as Huntington’s disease (Behrens et al., 2002, ALS 
(Rothstein et al., 1996), Alzheimer’s disease (Masliah et al., 1996), ischemia (Torp et al., 1995), 
and hippocampal sclerosis (Matthern et al., 1999).  Furthermore, mice deficient in GLT-1 show 
lethal spontaneous seizures (Tanaka et al., 1997).  
Here we report that pilocarpine-treated animals had higher levels of GLT-1 expression in 
the CA1 region of the hippocampus, but a decreased level of expression in the dentate region. 
VEGF treatment did not alter this pattern. Perhaps clearance of glutamate was not as efficient in 
the DG and the decreased level of expression is supportive of that; however in the CA1 area 




Glutamate transport is only the first step in the glutamate-glutamine cycle, so it would be 
interesting to examine glutamine levels after pilocarpine-induced seizures in animals receiving 
VEGF or inactive VEGF protein to determine if VEGF alters any other components of the 
glutamate-glutamine cycle.  Measuring the key enzymatic players in the cycle, GS or PAG, 
could provide clues about any effect of VEGF on this biochemical process.    
Astrocytes, VEGF & BBB  
Although VEGF's effects on astrocytes could directly impact hippocampal circuit 
function, it could also indirectly impact it via the important role of astrocytes in BBB integrity. 
The BBB brings nutrients and mediates efflux of waste products by restricting both ionic and 
fluid movement between the blood and brain. Astrocytes help by forming junctions with their 
end feet as well as assisting in the formation of the BBB and maintaining ionic balance. Reports 
also have found that the astrocyte precursor cells (APCs) are likely to induce endothelium 
development, and that interactions of astrocyte lineage cells and endothelium progressively 
generates the adult BBB (Barres et al., 2001). VEGF is a key player in driving vasculogenesis 
and endothelial proliferation (Yancopoulos et al., 1998) and APC’s may express VEGF that 
would drive these processes. In turn these endothelial cells would then drive the differentiation 
of the APCs into astrocytes (2001) that would then trigger the formation of the BBB. Astrocytes 
have direct contact with progenitor cells, endothelial cells and neighboring astrocytes. This view 
opens interesting questions regarding the ability of these cells to stimulate differentiation or de-
differentiation under certain conditions to resolve the changes that would lead to further toxicity. 
Given the responsibilities of astrocytes to maintain ionic balance it is possible that reactive 
astrocytes are changed and no longer able to maintain the integrity of the BBB due to loss of 
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cells and “neurovascular units”.  
Leakage of the BBB is associated with many neurological disorders including temporal 
lobe epilepsy. Work by Seiffert and colleagues (2004) suggest that focal opening or change in 
BBB may be epileptogenic due to accumulation of albumin and therefore important in the 
development of epilepsy disorders. Ivens (2007) showed that direct brain exposure to serum 
albumin is associated with uptake into astrocytes mediated by TGF-ß receptors, and is followed 
by downregulation of Kir 4.1 potassium channels which results in reduced spatial buffering of 
extracellular potassium. The net effect of this alteration would be increased extracellular 
potassium and NMDA receptor-mediated hyperexcitability.   
The Relationship of Astrocyte Changes to Behavioral Preservation  
 In addition, to the observed alterations in astrocyte morphology, our study revealed 
cognitive improvements in post-status animals treated with VEGF compared to animals 
receiving Inactivated VEGF. Correlational matrices revealed that astrocyte morphology changes 
in both size and complexity were predictors of the partial preservation of learning and memory.  
This suggests that these measures have a relationship with the behavioral findings, but it is 
important to note that this relationship is only correlational. No "cause and effect" statement can 
be confidently asserted about the impact of astrocyte morphology on circuit function. It is, 
however, possible that the preservation of a more normal astrocyte morphology in the VEGF-
treated animals allowed for an increased ability for astrocytes to contribute to axon re-wrapping 
and regeneration.  That is, although neurons were lost equally in both seized groups (VEGF vs. 
control), it is possible that that retention of normal astrocyte function allowed for the partial 
preservation we observed in learning and memory due to better functional recovery of the 
remaining neuronal circuit.   
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 Although earlier work from this lab found a full preservation of anxiety-related behaviors 
in VEGF-treated animals, the current study did not find statistically significant effects of either 
pilocarpine-induced seizures or VEGF treatment in the light/dark exploration task. Therefore, we 
could not assess the recovery of normal emotional behaviors in our experiments. 
Limitations & Future Directions 
 The current work had a number of limitations that represent opportunities for future work 
to more fully interpret our findings.  First, our study evaluated astrocyte morphology at only one 
time point. It would be illuminating to evaluate a timeline in which VEGF was administered 
right up to behavioral testing. Further, it would have been informative to be able to collect tissue 
at different time points throughout the month after status to determine whether the changes in 
astrocyte morphology observed one month after status were sustained throughout the post-status 
period.  Because of this limitation, it is difficult to fully evaluate whether VEGF was beneficial 
or detrimental. That is, it is possible that the behavior was improved because VEGF was no 
longer acting at the time of testing, and that it was VEGF withdrawal rather than VEGF 
treatment that was protective. The goal of the current studies was to see if treatment with VEGF 
around the time of status would result in long-lasting improvement without the need for chronic 
VEGF treatment. Additionally, it may be revealing to investigate the age of the astrocytes using 
markers such as glutathione transport or D-serine racemase which are only found in mature 
astrocytes but not mature NG2+ cells or young astrocytes (Parpura & Haydon, 2009). This may 
reveal more specific information regarding the astrocyte characteristics and VEGF effects. For 
instance, it is possible that VEGF has different effects that are dependent upon the age of the 
astrocyte or it could be that the astrocytes investigated were of different ages. 
 Given the finding of a possible alteration in Glt-1 levels with VEGF in CA1, future 
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studies are warranted to address the astrocyte glutamate-glutamine cycle as well as to expand our 
information about VEGF's potential effects on other aspects of the cycle such as GS and PAG.  
Any impairment in these important parts of the cycle which regulate the glutamate levels and 
provide neurons with glutamine could impact circuit function. This information could provide a 
more complete picture of any disruptions or dysfunction in this important system in the balance 
of excitation and inhibition. 
 One methodological limitation of this study was the use of GFAP to immunostain 
astrocytes, which is now thought to only prominently stain a subset of astrocytes.  In addition, 
using this stain does not allow for the distinction between types of astrocytes nor does it allow us 
to determine the age of astrocytes, a factor that is suspected to affect astrocyte function. The 
heterogeneity of astrocytes may reveal the functional diversity of subtypes of astrocytes and their 
particular interactions with other cell types may reveal important information regarding the 
specific subtypes of astrocytes that contribute to the metabolism of neurotransmitters.  
In addition to having multiple subtypes of astrocytes, the hippocampus is, of course, 
invested in a wide variety of other cell types. The current study focused on astrocyte morphology 
changes in seized and non-seized animals treated with either Inactivated VEGF or VEGFA165 
protein. However, it is unlikely that VEGF only impacts astrocytes, and its impact on other cell 
types in the brain could be equally or more important. VEGF could, for instance, impact 
microglia or endothelial cells through their expression of VEGFR1 and other VEGF receptors. 
Indeed, we can't rule out the possibility that VEGF's effects on astrocytes are themselves 
indirect, occurring through intermediaries such as microglia, endothelial cells, or neurons.  In 
complex systems such as the brain, any impact of VEGF on one system has the potential to alter 
others, and if that impact includes alterations in excitability, the net effect of that impact 
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becomes even stronger within the context of epilepsy.  Indeed, while our VEGF-treated animals 
did not have statistically different seizure severity scores or latencies to seize, we have not 
verified that post-status excitability is not altered at the circuit level by VEGF. It would be 
important in future studies to use video-EEG technology during and after SE to allow for a more 
refined measurement of seizure activity. If VEGF were found to cause alterations in excitability 
after SE, which seems possible given prior work suggesting reduced excitability with VEGF 
treatment (McCloskey et al., 2005), it might be expected to change any parameter that is 
influenced by the excitability of the circuit.  VEGF's promise as a potential seizure therapeutic is 
unaltered by the results of such an investigation, but the interpretation of the mechanisms 
underlying its beneficial effects could change. 
Therapeutic Utility of VEGF in Epilepsy 
More and more evidence is accumulating for astrocyte modulation as a target for clinical 
therapeutic interventions.  However, this approach requires the necessity to understand the 
complex interactions between glial cells, neurons, progenitor cells and endothelial cells making 
the research ahead vast.  If VEGF does preserve the normal size and complexity of the astrocytes 
and their processes, and allows for normal inter-astrocyte distance, it may facilitate the astrocytes 
maintaining their organizational domains. It is possible that by preventing changes in astrocyte 
size, complexity, and organization after seizures, VEGF may preserve the level of 
thrombospondins or other growth factors, thereby contributing to the ability of the adult brain to 
recover from the damaging consequences of seizure activity.  VEGF itself is not likely to be a 
viable therapeutic option for epilepsy because it is a large protein that does not cross the blood-
brain barrier.  However, manipulating the VEGF pathway using other approaches could serve as 
a future therapeutic for preventing the long-term sequelae of epilepsy.  More research will be 
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